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G-protein coupled receptors (GPCRs) function as both gatekeepers and molecular 
messengers of the cell. They relay signals that span the cell membrane mediating nearly 
every significant physiological process and currently represent the target of about 30% of 
all drugs. The signals they transmit can arise from a remarkable variety of stimuli which 
includes, but is not limited to, photons, neurotransmitters and hormones. GPR55, a 
rhodopsin-like (Class A) GPCR, has received a great deal of attention due to its emerging 
involvement in a multitude of physiological processes and its putative identity as a third 
type of cannabinoid receptor. Characterizations of GPR55 knock-out mice reveal a role 
for the receptor in controlling inflammatory pain, neuropathic pain, and bone resorption.1 
Myriad other studies indicate that GPR55 activation may play a part in oncogenesis and 
metathesis.  
GPR55 can be found in numerous tissue types throughout the body and is also 
highly expressed throughout the cerebellum and surrounding central nervous system 
lending credence to the idea that this receptor may play a more crucial physiological role 
than originally thought.2 GPR55 has an extensive physiological profile and has been 
shown to respond uniquely to a great number of diverse compounds. Specifically, it has 
been shown to recognize many cannabinoid compounds, including CB1 and CB2 
endogenous ligands, phytocannabinoids and synthetic cannabinoids. Similar to the 
ligands of the CB1 and CB2 receptors, the endogenous ligand of GPR55, 
 
 
lysophosphatidylinositol (LPI), is a lipid-derived molecule.3 LPI activates ERK1/2 and 
increases [Ca2+] and, to date, there has been no evidence that LPI interacts with the other 
cannabinoid receptors.  
Despite innumerable prospective clinical uses hinted at by the aforementioned 
research no low nanomolar potency ligands of GPR55 have been identified. Nor has there 
been a radio-ligand developed to characterize the binding site of this receptor. Lack of 
such tools is a great impediment to any forward progress towards developing the GPR55 
receptor as a therapeutic target for drug design.  
The following research details the creation of both a GPR55 active- and a GPR55 
inactive- state homology model. Towards this goal, Chapter I details the background of 
the discovery, pharmacological relevance and ligand scope of GPR55. Its purpose is to 
establish a framework for the research that follows and highlight the medical importance 
of this elusive receptor. 
Chapter II describes the synthetic preparation of antagonists of GPR55 for use in 
preliminary SAR studies. The original high throughput screen that lead to the 
identification of novel GPR55 scaffold chemotypes from the screening of over 300,000 
compounds gave rise to the piperidinyloxadiazolone compound CID23612552 and the 
synthetic diversification of what was then dubbed Scaffold 1. 
 A detailed description of the methods used in the construction of the updated R 
and R* state of GPR55 models is handled in Chapter III. A combination of 
Conformational Memories4,5 (using the CHARMM forcefield), Ligand Conformational 
Analysis (performed using Spartan (Wavefunction, Inc., Irvine, CA)) and 
 
 
Macromodel/Maestro/Glide (from the Schrödinger suite) was used to build and refine 
both GPR55 model states.  
Chapter IV then covers model validation and refinement. Using the 
phenylpiperazine (ML184 CID2440433) and mutations performed in the lab of Dr. Mary 
Abood (Temple University) it was shown that the current iteration of the GPR55 R* 
model was indeed a valid representation of the activated state of this receptor. This 
chapter also provides information that gives rise to the “Future Directions” chapter, 
Chapter V. 
This final chapter is a look forward to the research that still remains to be done to 
ensure that these models will function as the accurate tools that they have the potential to 
be. We used the GPR55 R bundle to suggest antagonist structures that will maximize 
ligand/receptor interactions and hopefully give rise to nanomolar potency molecules. 
These ligands will need to be synthesized and tested. We also identified key residues in 
the active bundle (GPR55 R*) that could be mutated to enhance or verify ligand binding. 
Mutations that destroy receptor function, while interesting, would not have the same 
utility as the aforementioned kinds of mutations. 
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CHAPTER I 
 
THE GPR55 STORY: DISCOVERY, PATHOPHYSIOLOGICAL RELEVANCE 
AND LIGAND SCOPE 
 
 
Introduction 
G-protein coupled receptor 55 (GPR55), first identified and cloned in 1999, is a 
receptor in the Class A (rhodopsin-like) G protein-coupled receptor (GPCR) family. This 
receptor is expressed in myriad tissue types throughout the human body and is 
particularly populous in human striatum1 (Genbank accession # NM-005683; Figure 1). 
In an attempt to discover ligands that could modulate GPR55 activity, screening assays 
were carried out on cannabinoid libraries by AstraZeneca2 and GlaxoSmithKline3. It was 
discovered that GPR55 responded not only to endogenous or plant-derived CB1R/ CB2R 
ligands but various synthetically derived cannabinoid compounds as well. These findings 
sparked a debate that has raged for over a decade as to the veracity of classifying GPR55 
as a novel, third type of cannabinoid receptor belonging in the same subfamily as 
cannabinoid receptors CBR1 and CBR2.4-6 
The CB1 and CB2 receptors themselves are compelling targets for their potential 
as modifiers of drug abuse and addiction and it is thought that, if GPR55 is indeed related 
to these receptors it could have a similar role. Characterizations of GPR55 (-/-) (knock-
out) mice7,8 have shown a definite role for the GPR55 receptor in inflammatory pain, 
neuropathic pain, and bone development with more recent studies indicating that the 
receptor may play an even more pervasive role in both energy metabolism and cancer 
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motility.9,10 These results suggest that the ability to manipulate the active and inactive 
state of GPR55 has tremendous therapeutic potential.  
 
 
Figure 1. Human Striatum. 
 
Discussing the pharmacology of GPR55 in a precise manner is a perplexing task 
at best: Certain CB1 and CB2 antagonists have been reported to act as agonists at GPR55 
while other CB1/CB2 agonists have been reported to act as antagonists.11 Adding to the 
already puzzling responses of the receptor was the identification of LPI 
(lysophosphatidylinositol) as the endogenous ligand for GPR55.12 This lysophospholipid 
has been described as having an EC50 of 200nM to 49nM13 by Henstridge et al. in 2009, 
but later data collected on LPI’s effect on GPR55 has appeared to differ from lab to lab 
and from assay to assay.  
One strategy for navigating the seemingly contradictory pharmacology of GPR55 
is to step back and try to understand this receptor from the “ground” up. To do this one 
must first understand the basic morphology of GPCRs and GPR55 and its ligands 
specifically. 
 
Striatum 
Caudate 
Nucleus
Putamen 
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GPR55 Structure 
GPR55 is one of many integral membrane proteins made up of seven membrane-
spanning domains known transmembrane helices.14,15 This receptor is related to receptors 
of rhodopsin-like GPCRs (Class A) and shares many of their key sequence motifs (see 
Figure 2).  
 
Figure 2. GPCR General Structure. 
 
The human GPR55 (hGPR55) sequence is relatively unique and only shares low 
sequence identity with the cannabinoid receptors CB1R and CB2R (13.5% and 14.4%, 
respectively) described previously. The GPCR proteins displaying the highest 
percentages of homology with GPR55 are the ẟ-Opioid (28%), GPR35 (27%), P2Y 
(29%), GPR23 (30%), CCR4 (23%), LPA4 (30%) and LPA5 (30%).1,16 A helix net 
representation of the GPR55 sequence is displayed in Figure 3.17 
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Figure 3. GPR55 Sequence in Helix Net Form. 
 
The most highly conserved residues across Class A GPCRs are as follows: TMH1 
- N1.50, TMH2 - D2.50, TMH3 - E/D3.49, R3.50, Y3.51 (DRY motif), TMH4 - W4.50, 
TMH5 - P5.50, TMH6 - C6.47, W6.48, X (this residue varies), P6.50 (CWXP motif), and 
TMH7 - N7.49, P-7.50, X, X, Y7.53 (NPXXY motif).* This conservation of residues and 
the convenient Ballesteros-Weinstein18 numbering system make sequence patterns easily 
identifiable on multiple sequence alignments and allow for easy comparison among 
residues in the transmembrane regions of different receptors. While GPR55 possesses 
some of the highly conserved .50 residues (N1.50, D2.50, W4.50 and P5.50) found in 
many GPCRs, there are a few no-table differences. GPR55 has a conservative 
substitution (DRF) for the TMH3 E/DRY motif, a conservative substitution (SFLP) for 
the TMH6 CWXP motif, and a non-conservative substitution (DVFCY) for the THM7 
NPXXY motif. This sequence divergence is thought to lead to an altered level of 
hydration and local transmembrane flexibility and, consequently, gives rise to a distinct 
conformation in this region.19 Outside of the TMH region, GPR55 has an extracellular-1 
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(EC-1) loop that is shorter than most (three residues versus the six found in β2-AR and 
Rhodopsin) and an EC-3 loop that is noticeably longer (fourteen residues long versus the 
five in β2-AR and the six residues in rhodopsin, CB1 and CB2). Located on the EC2 loop 
there is a cysteine (C168) that is thought to form a disulfide bond with C3.25.11,17 This 
EC2 disulfide bond, while present in many Class A GPCRs (CXCR4, P2Y12, DOR, etc.) 
is absent in both CB1 and CB2.  
To date there has been no x-ray crystallographic structure resolved for GPR55. 
Numerous homology models based on available GPCR crystal structures have been 
reported however, and will be discussed later in this chapter.17,19     
*[The Ballesteros–Weinstein numbering scheme is based on the presence of 
highly conserved residues in each of seven transmembrane (TM) helices. It consists of 
two numbers where the first denotes the helix, 1–7, and the second the residue position 
relative to the most conserved residue, defined as number 50. For example, 5.42 denotes 
a residue located in TMH5, eight residues before the most conserved residue, Pro5.50]   
Pharmacology 
CBR1 and CBR2 are themselves compelling medical targets for their potential as 
modifiers of drug abuse and addiction and it is thought that, if GPR55 is indeed related to 
these receptors, it could have a similar role. As mentioned in the introduction, the 
pharmacological reports of GPR55 activity are far from clear. The jury remains out for a 
large section of the research community as to whether GPR55 represents a new subtype 
of cannabinoid receptor or just a novel cannabinoid receptor modulator. Getting an 
answer to this question and finding an infallible way to operate the active and inactive 
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states of GPR55 will grant tremendous therapeutic power to medicinal chemists in the 
near future.  
To discuss the pharmacology of GPR55 in a precise manner is a perplexing task at 
best: While cannabinoid receptors couple to G-proteins of the Gi/0 subfamily, as widely 
demonstrated in the literature,20,21 GPR55 has been seen to associate with a number of 
different G-proteins: Gα13,13 Gαq/11,23 Gαq/Gα124 or Gα12/1313,25; and its lack of coupling 
specificity seems to depend on the ligand used and the cell line in which the receptor is 
expressed. A range of signaling pathways can be initiated based on GPR55’s interaction 
with individual G proteins: RhoA, MAPK cascades, actin filament formation and 
intracellular calcium release via the activity of phospholipase C (PLC). The resulting 
cascades ultimately end in the activation of extracellular signal-regulated kinase (ERK), 
RhoA activated kinase (ROCK) or phosphatidylinositol 3-kinase (PI3K). In addition, two 
transcription factors, NFAT or NFkB (that translocate to the nucleus and modulate the 
expression of different genes), can also be induced following GPR55 activation.13,25 
The evaluation of novel potential GPR55 ligands has been vigorously explored 
through numerous assays with differing functional endpoints: GTPγS binding,7 analysis 
of intracellular calcium levels,26,28 phosphorylation of ERK1/2,19,29 and the activation of 
the small GTPase proteins Rac1, RhoA and Cdc42.26,28,30 Maintaining consistency 
between pharmacological assays has proven to be very problematic however, due to 
promiscuous nature of GPR55’s response to ligands. It is a fundamental experimental 
problem when GPR55 ligands modulate not only the eponymous receptor but also CBRs, 
transient receptor potential vanilloid channels (TRPVs), or peroxisome proliferator-
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activated receptors (PPARs).29,31,32 Moreover, clear monitoring of the signaling of this 
receptor may be dependent on intrinsic properties of GPR55 specifically. Unknowns, 
such as additional active conformation states,28 oligomerization,29,31,32 allosterism,33,34 or 
biased agonism could play a pivotal role in getting the receptor to signal robustly and 
consistently. 8,25,30,31 These considerations, and more, have been the topic of many recent 
reviews written on GPR55, demonstrating the growing interest in resolving the 
pharmacological conundrums of this receptor.11,38,39  
Biological Relevance of GPR55 
GPR55 is ubiquitously expressed throughout the body; however, its primary 
physiological function still remains to be fully understood. The receptor has been shown 
to co-localize with both CB1R and CB2R.29,32 This indicates that GPR55 is extensively 
expressed throughout the CNS (hippocampus, putamen, caudate, thalamic nuclei) as well 
as being found in osteoclasts, kidneys and peripheral tissues such as the immune system 
(spleen, tonsil)7,23,39,40,41 GPR55 is also expressed in vascular endothelial cells and this 
has led various research groups to study the involvement of GPR55 in the regulation of 
vascular functions.6,42-44  
There is increasing evidence that GPR55 plays an integral role in the modulation 
of inflammatory and neuropathic pain. Activation of GPR55 enhances neuronal 
excitability by increasing intracellular Ca2+ and suppressing the K+ current acting on M-
type channels as is seen in pro-nociception (the biological amplification of pain signals). 
24 Moreover, Staton et al.8 showed that mice lacking GPR55 did not display hyperalgesia 
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upon inflammatory or neuropathic stimuli. Results from experiments in microglial cells45 
and with neutrophils46 further support the role of GPR55 in the inflammatory process.  
A recent emerging body of evidence that points to the contribution of GPR55 to 
metabolic regulation and energy homeostasis.47-49 Correlations between body weight and 
levels of GPR55 expression in visceral adipose tissue has been reported and it is clear 
that GPR55, along with CB1R, controls food intake, gut motility and insulin secretion. 
GPR55 also appears to have myriad, secondary roles in other complicated disease 
states. There is evidence that the receptor plays a crucial part in the physio-pathology of 
cancer. Increased levels of LPI, the putative GPR55 endogenous ligand, have been found 
in plasma and ascites in patients with this pathology.50,51 Moreover, GPR55 expression is 
significantly increased in tumor tissues as compared with their healthy counterparts and 
its expression may be able to be used as a potential biomarker in oncology cases 
associated with poor prognosis.52,53 As mentioned previously, GPR55 signals through 
Rho GTPases, which control cytoskeleton organization, cell polarity and cell migration, 
and are closely related to tumor progression.54-56 Consequently, activation of GPR55 
triggers a number of signaling cascades that stimulate cancer cell proliferation, migration, 
and invasion. These findings support the idea that GPR55 would make an excellent 
oncological therapy target in in the ongoing fight against cancer.  
Perhaps related to GPR55s ability to induce fibril formation and cancer cell 
migration is its effect on bone physiology. Whyte et al.57 reported that manipulation of 
GPR55 signaling seems to regulate osteoclast polarization and bone resorption activity. 
Hence, GPR55 may represent a novel target for treatments of arthritis and bone loss 
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associated with osteoporosis. It is worth noting that GPR55 is not involved in the 
regulation of CNS development, gross motor movement or learned behavior. It does seem 
however, to play a role in motor coordination.58 The physiological, therapeutic potential 
of GPR55 modulation is schematically summarized in Figure 4. 
 
Adapted from Henstridge et al.59 
 
Figure 4. Pathophysiological Roles of GPR55. 
 
There is an extraordinary array of evidence that implicates GPR55 in the 
modulation of diverse physio-pathological conditions, but issues still remain with 
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experimental consistency. It is clear that a drive to secure nanomolar, selective ligands of 
GPR55 is of utmost future importance. 
GPR55 Ligands 
Due to a lack of information of GPR55 three-dimensional structure and the 
complexity of interpreting GPR55 functionality assays, the design of potent and selective 
GPR55 ligands remains a major challenge for medicinal chemists. The following section 
is a categorization of different GPR55 modulators that have been reported so far in the 
literature. 
Endogenous Ligands 
Despite the contradictory data reported for many GPR55 ligands, the bioactive 
lipid lysophosphatidylinositol has demonstrated GPR55 agonism in all studies and 
functional assays reported so far.25,41 Compilation of this data led to the proposal that LPI 
is an endogenous non-CB1R/ non-CB2R ligand of GPR55. Structurally, LPI contains a 
glycerol core esterified with a single fatty acid in either the sn-1 or sn-2 position and an 
accompanying inositol substituted phosphate group.12,64 In a recent study performed by 
Oka et al.,26 for identification of the molecular species of LPI in the rat brain, it was 
found that the predominant fatty acyl moiety was stearic acid (50.5%), followed by 
arachidonic acid (22.1%). 2-Arachidonoyl-containing LPI species (2-AGPI) displayed the 
highest potency and efficacy of the LPI species published to date (Figure 5). Due to this, 
2-AGPI has been proposed as the natural LPI ligand for GPR55.26,65 
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Figure 5. The Structures of Lysophosphatidylinositol (LPI) and its 2-arachidonoyl-
derivative (2-AGPI). 
 
The ability of LPI to activate GPR55 has been confirmed in various cellular 
systems and pharmacological outcomes. For instance, increase of LPI levels has been 
detected not only  in diverse tumors but also in cancer cell proliferation and tumor 
progression processes.6 LPI induces phosphorylation of ERK and elicits a rapid Ca2+ 
transient (a brief increase in calcium ion) in GPR55-expressing cells.12 Further reports 
have supported these findings in HEK293 cells expressing GPR55 and in large-diameter 
DRG neurons24 and endothelial cells.23 Henstridge et al.13 showed that LPI stimulates 
Ca2+ release that is dependent on Gα13 and RhoA activation and in β-arrestin 
PathHunterTM assays,  LPI is also revealed to be a potent agonist.63 
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Cannabinoid-related Ligands of GPR55 
Endocannabinoids and derivatives. Several endogenous cannabinoid ligands 
have been identified as GPR55 modulators (Figure 6). Anandamide, the predominant 
endocannabinoid, has displayed inconsistent results in GPR55 assays. This lipid 
neurotransmitter stimulated [35S]GTPγS binding in the nanomolar range and caused 
calcium mobilization in the micromolar range, yet did not affect phosphorylation of ERK, 
β-arrestin signaling or receptor internalization. Two-arachidonoylglycerol, another 
significant endocannabinoid, showed agonist efficacy in a [35S]GTPγS binding assay but 
was ineffectual in β-arrestin recruitment and GPR55 internalization. These discrepancies 
may be due to the aforementioned incongruities between functional assays or cell 
systems36 and, in accordance with IUPHAR (International Union of Basic and Clinical 
Pharmacology), do not demonstrate irrefutably that these eicosanoids are in fact GPR55 
agonists. 
Other endocannabinoids such as palmitoylethanolamide, noladin ether, 
virodhamine and oleylethanolamide resulted in [35S]GTPγS binding in transiently 
transfected hGPR55-HEK293 cells, with EC50 values of 4, 10, 12 and 440 nM 
respectively.7 Results similar to these were previously reported by AstraZeneca in the 
same [35S]GTPγS assay.2 According to those GTPγS studies, anandamide activated 
GPR55 and CBRs with similar potencies while palmitoylethanolamide, virodhamine and 
2-AG displayed selective action through GPR55. 
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Figure 6. Endocannabinoids as GPR55 Ligands. 
 
Phytocannabinoids and related molecules. Bioactive constituents from the plant 
Cannabis sativa and synthetic analogues (Figure 7) have also shown discrepant data 
regarding their GPR55 pharmacology. Delta9-THC exhibits activation of GPR55 in 
[35S]GTPγS binding, RhoA assays and intracellular Ca2+ mobilization in transiently 
transfected hGPR55-HEK293 cells1,2,24 but was unable to stimulate ERK1/2 
phosphorylation or β-arrestin recruitment.12,63 It remains to be seen whether these results 
are a consequence of experimental variability, differences in functional readouts or 
GPR55 intrinsic properties. HU210, a synthetic derivative of Δ9-THC, also displayed 
activity as GPR55 agonist in diverse assays while being inactive in others.7,2,63 
Abnormal-cannabidiol (Abn-CBD) and the structurally related O-1602 have been 
reported as GPR55 selective agonists in [35S]GTPγS assays with EC50 values in the 
micromolar and nanomolar ranges respectively.7,6,2 Nevertheless, as has been observed 
with other GPR55 ligands, there have been research groups who reported a lack of 
activity when using different cellular systems or functional endpoints.26,63 
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The potent CB1R/CB2R agonist CP55,940 has also shown conflicting data when 
used to stimulate GPR55, acting as an agonist in [35S]GTPγS assays7,2 and antagonist23,12,5 
in β-arrestin, ERK phosphorylation and Ca2+ mobilization tests. 
 
Figure 7. Structure of GPR55 Active Phytocannabinoids and Synthetic Derivatives 
Related to Δ9-THC. 
 
Of the other phytocannabinoids, such as cannabinol and JWH133, initial studies 
confirmed their inactivity towards GPR55.36 However, in a recent, more sensitive ERK 
assay, developed by Sharon Anavi-Goffer et al.,33 it was determined that JWH133 could 
reduce basal pERK acting as GPR55 inverse agonist. From the same GPR55 assay, the 
phytocannabinoids Δ9-tetrahydrocannabivarin, cannabidivarin and cannabigerovarin 
acted as potent inhibitors of LPI and could constitute a new set of novel GPR55 ligands.  
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CBD, a phytocannabinoid seen recently in headlines for its omnipotent “curative” 
powers and whose mechanism of action is not fully understood, has also shown 
promising GPR55 pharmacological activity. This non-psychoactive component of 
marijuana acts as GPR55 antagonist preventing [35S]GTPγS binding and Rho 
activation7,57,66 and was inactive in Ca2+ mobilization assays24 and β-arrestin 
recruitment.63 Conversely, O-1918, a synthetic derivative of CBD that does not bind to 
CBRs67 acted as a GPR55 antagonist in intracellular Ca2+ functional analysis using 
endothelial cells that express GPR55.42 
Synthetic cannabinoid ligands. 
Arylpyrazoles. The arylpyrazole scaffold has been extensively explored in the 
cannabinoid world, becoming very relevant in the design of CB1R or CB2R inverse 
agonists or antagonists (Figure 8). Rimonabant (SR141716A), the familiar CB1R 
arylpyrazole antagonist, has been found to behave as a GPR55 agonist in some 
assays2,25,63,68 but as a GPR55 antagonist in others,23,24,69 exerting no effect in one 
additional study.12 In comparison, SR144528, a potent CB2R antagonist, is inactive in all 
the GPR55 assays reported so far. It did not induce a rise in calcium in transiently 
transfected hGPR55-HEK293 cells nor in β-arrestin binding assays.24,63 Also studied 
extensively were AM251 and AM281, CB1R antagonists structurally related to 
SR141716A. AM251 behaved as a GPR55 agonist in different biochemical  
assays,3,5,7,13, 25,63,68 while AM281 did not seem to interact with the receptor7 or displayed 
very weak agonist effects.27, 45 
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Figure 8. Arylpyrazoles SR141716A, AM251, AM281, and SR144528. 
 
The CB1R antagonists SR141716A, AM281 and AM251 can act as agonists while 
also acting as inhibitors of LPI inducing activation of ERK phosphorylation within the 
same cellular model. This may explain the seemingly conflicting data surrounding the 
GPR55 pharmacology of several CB1R and/or CB2R ligands. It suggests that certain 
arylpyrazole ligands may act in a bitopic fashion at GPR55.69 
In 2010 Daly et al.43 reported that the fluorescent ligand T1117 activated GPR55 
by promoting a characteristic oscillatory Ca2+ response in HEK293 cells stably 
expressing recombinant GPR55. This molecule, structurally analogous to the CB1R 
ligand AM251 but linked to a fluorescent tetramethylrhodamine group, showed weak or 
no affinity towards CB1R.  
Aminoalkylindoles. The CB1R/CB2R agonist WIN55,212-2 has been used 
extensively to probe the endocannabinoid system (Figure 9). This significant amino-
alkylindole does not display any activity at GPR55. Consistent data from various 
biological assays confirm that WIN55,212-2 does not bind GPR55 either as an agonist or 
an antagonist.7,2,24 JWH015, a WIN55,212-2 analogue was, however, able to activate 
GPR55 in [35S]GTPγS assay with EC50 value in the nanomolar range and was effective at 
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micromolar concentrations in Ca2+ mobilization assays.24 Moreover, data from an 
ERK1/2 phosphorylation assay suggests that the CB2R agonist GW405833 is a bitopic 
ligand of GPR55, acting as a partial agonist of GPR55 alone or as an allosteric modulator 
enhancing LPI signaling.33 
 
Figure 9. Synthetic Cannabinoid Ligands WIN55,212-2, JWH015, and GW405833.  
 
Coumarins. The coumarin scaffold has shown great potential and versatility in 
the development of potent and highly selective CBRs ligands.70 Reexamining this 
scaffold, using β-arrestin recruitment assays, uncovered 3-substituted coumarins as novel 
GPR55 antagonists.34 Interaction with CBRs require a lipophilic substituent in position 7 
(PSB-SB-487, Figure 10) while having a methyl at position 8 is favorable for GPR55 
antagonism (PSB-SB-489, Figure 10). Deng et al.71 have developed computational QSAR 
models so that they might design coumarin derivatives with enhanced potency.  
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Figure 10. 3-(2-Hydroxybenzyl)-5-isopropyl-8-methyl-2H-chromen-2-one (PSB-SB-489) 
and 7-(1,1-dimethyloctyl)-5-hydroxy-3-(2-hydroxybenzyl)-2H-chromen-2-one (PSB-SB-
487). 
 
Magnolol derivatives. Magnolol (Figure 11) is one of the main bioactive 
compounds in the bark of Magnolia officinalis.72 This biphenylic compound and other 
related lignans are able to modulate CB1R and CB2R.73 Magnolol acts as a partial 
CB1R/CB2R agonist whereas its major metabolite, tetrahydromagnolol, is a potent 
peripheral CB2R agonist that acts as a weak antagonist of GPR55.74 In a notable study, 
Müller et al.75 developed structure-activity relationships of new magnolol analogues by 
varying the alkyl chains and the phenolic groups. They demonstrated that methylation of 
one of the hydroxyl groups (5´-hexyl-2´-methoxy-5-propylbiphenyl-2-ol) maximizes 
antagonistic potency when binding to GPR55. This structure represents an untapped 
potential lead compound in the development of new GPR55 antagonists. 
 
O
OH
5´-Hexyl-2´-methoxy-5-propylbiphenyl-2-ol
OH
HO
Magnolol
OH
HO
Tetrahydromagnolol  
Figure 11. Magnolol and Analogues. 
Pos. 8 
Pos. 7 
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Non-cannabinoid Related Ligands of GPR55 
The growing evidence that illuminates GPR55s involvement in innumerable 
biological pathways has generated great interest in this receptor as a therapeutic target.  
The logical next step in maximizing this receptor’s potential was the focused 
drive towards the identification of new selective GPR55 ligands. This drive gave rise to a 
collaborative project spanning three different laboratories and the Sandford-Burnham 
screening center of the Molecular Libraries Probe Production Centers Network 
(MLPCN)76,77 and allowed for the identification of six different GPR55 chemical 
scaffolds.76,77 This study began with high-throughput screening of a library of compounds 
using β-arrestin assays in U2OS cells permanently expressing HA-GPR55E and βarr2-
GFP.5 As seen in Figure 12, Phenylpiperazine (CID2440433), triazoloquinoline 
(CID1172084) and morpholinesulfonylphenylamide (CID15945391), represent the potent 
GPR55 agonists discovered in this study77 while  piperidinyloxadiazolone 
(CID23612552), thienopyrimidine (CID1434953) and quinoline aryl sulfonamide 
CID1261822 are representative GPR55 antagonists.76  
Parallel studies,68 undertaken by GlaxoSmithKline in 2011, validated the 
previously GSK developed benzoylpiperazine as a GPR55 agonists in Saccharomyces 
cerevisiae yeast and in HEK293 cells. GSK494581A, the most potent ligand, and 
GSK575594A, the most selective one, had been patented prior to this discovery as 
glycine transporter subtype 1 inhibitors (being 60-fold selective for GPR55) (Figure 13). 
Of note is the result that these ligands activate human but not rodent GPR55, hinting at 
important differences in the binding pocket of the two orthologs. 
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Figure 12. GPR55 Agonist Scaffolds (CID2440433, CID1172084, and CID15945391) 
and GPR55 Antagonist Scaffolds (CID23612552, CID1434953, and CID1261822) from 
HTS. CID16020046 Represents Another GPR55 Antagonist Recently Described by Kargl 
et al.72 
 
 
Figure 13. Benzoylpiperazines Previously Reported as Glycine Transporter Inhibitors. 
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In 2013, Kargl et al. identified CID16020046 (Figure 12) as a selective GPR55 
antagonist.78 This compound originated from the same MLSCN (Molecular Libraries 
Screening Centers Network) screen mentioned above; however, it was not selected by 
those researchers for further development at that time. This molecule antagonizes 
agonist-mediated GPR55 activation in yeast cells and inhibits GPR55-mediated 
intracellular Ca2+ release. CID16020046 reduces LPI signaling in primary human lung 
microvascular endothelial cells (HMVEC-L) and in human platelets suggesting yet 
another novel therapeutic application for GPR55. 
An analogue of (R,R´)-fenoterol (a short-acting β2-adrenergic agonist), with a 573-
fold greater selectivity for β2-AR than β1-AR, has been shown to reduce GPR55 agonist 
efficiency.79 The compound, (R,R´)-4´-methoxy-1-naphthylfenoterol (MNF, Figure 14),  
exerts selective inhibition of GPR55 signaling as demostrated in various assays with 
readouts for ERK phosphorilation and cell motility. (R,R´)-MNF has been shown to 
reduce the pro-oncogenic activity of GPR55 thus revealing its therapeutic potential as an 
antitumor agent. 
 
 
Figure 14. Naphthylfenoterol (MNF). 
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An analysis of the vast range of GPR55 scaffolds reported to this point may help 
to elucidate the structural motifs involved in modulating the activity of this receptor. It is 
hoped that this information will contribute to the work being done in the rational design 
of new compounds able to selectively and potently bind this promising target.  
The construction of a comprehensive and current model of both the active and 
inactive state of the GPR55 receptor was therefore necessitated by the aforementioned 
results. Development of a binding site template, to guide the design of novel ligands with 
which to control the activation of this receptor, has the potential to be a vast and 
relatively unexploited therapeutic source. To date, no low nanomolar potency ligands 
have been identified or synthesized, nor has there been a radioligand developed to 
characterize binding at this receptor. The goal of the following research to be presented 
was the building, refinement and testing of two GPR55 receptor prototypes (an active 
state model and an inactive state model) to be used as a tool for exploring the ligand 
binding site. This predictive structure is essential for screening of current synthetic 
analogs and for the improved design of higher potency ligand profiles. Combining the 
extrapolative power of modern computational methods with the structure activity 
feedback from collaborating biochemists allows for a complete picture of the functioning 
model of GPR55 to be recognized. 
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CHAPTER II 
 
DESIGN, SYNTHESIS, AND ANALYSIS OF ANTAGONISTS OF GPR55: 
PIPERIDINE-SUBSTITUTED 1,3,4-OXADIAZOL-2-ONES 
 
Introduction  
 The work described herein began as a collaborative project between the Reggio 
and Abood labs and the Sanford Burnham Screening Center of the Molecular Libraries 
Probe Production Centers Network (MLPCN). A series of GPR55 antagonists belonging 
to novel GPR55 antagonist chemotypes and having IC50s in the 0.34 to 2.72 µM range 
were identified (8). These compounds were then screened for agonist activity with 
GPR55 along with agonist/antagonist activity at both the CB1 and CB2 receptors. Several 
of the GPR55 antagonists identified were completely selective. Structure-activity 
relationship (SAR) studies of chemotype one were began in the synthetic lab of Dr. Mitch 
Croatt. The results of initial ChemNavigator compound database substructure searches 
for Scaffolds 1-3 were used to guide the development of the research strategy to be 
presented in this chapter. Given GPR55’s complicated pharmacological profile it is 
unsurprising that search results varied widely between scaffolds. Scaffold 1 had only 5 
hits in the Aldrich database with a Tanimoto similarity of 70% or greater. Scaffold 2 
(which will be expounded upon in Chapter IV) had 91 unique hits from the Aldrich 
database, of which only 39 could truly “fit” in the original GPR55 model. In contrast, 
Scaffold 3 had 161 unique hits from the Aldrich database, with all regions of space 
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sampled quite well. The readily available commercial analogs of scaffolds 2 and 3 lead to 
Scaffold 1 being chosen for initial ligand diversification.  
The synthetic route was only three steps from simple starting materials: amide 
bond formation between the carboxylic acid and piperidone,33 reductive amination of a 
hydrazide and the ketone,34 and a carbonylative cyclization35 (Scheme 1; Figure 15). 
 
Figure 15. Scheme 1: Synthetic Scheme for Scaffold 1. 
 
Figure 16 shows a subset of the available R-groups and Aryl-groups that were 
initially examined. It is also important to note that all of the commercially available 
analogues of parent compound 1 had the same phenyl group (Ar = Ph). The synthetic 
route proposed allowed for this position to be modified in hopes to observe a direct effect 
on the IC50 values. In the original model the carbonyl of the azoxazolone interacts with 
K2.60 so it is hypothesized that if we place electron-rich aryl-groups next to this 
heterocycle, we could strengthen the interactions between the ligand and the receptor. 
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Figure 16. Subset of Available R-groups and Aryl-groups That Were Initially Examined. 
 
The overarching goal of the research presented in this chapter was the creation of 
a manageable library of synthetic antagonists with which to begin revision of the GPR55 
model. It was postulated that results from the antagonist synthesis combined with 
mutation data from the Abood lab would aid in the revision of the initial GPR55 model 
that had been created in the Reggio lab. The revised model would then be used to guide 
synthesis of new ligands and allow for a chem-informatics search for additional 
chemotypes.  
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Design, Synthesis, and Analysis of Antagonists of Gpr55: Piperidine-Substituted 
1,3,4-Oxadiazol-2-Ones 
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Abstract 
A series of 1,3,4-oxadiazol-2-ones was synthesized and tested for activity as 
antagonists at GPR55 in cellular beta-arrestin redistribution assays. The synthesis was 
designed to be modular in nature so that a sufficient number of analogues could be 
rapidly accessed to explore initial structure-activity relationships. The design of 
analogues was guided by the docking of potential compounds into a model of the inactive 
form of GPR55. The results of the assays were used to learn more about the binding 
pocket of GPR55. With this oxadiazolone scaffold, it was determined that modification of 
the aryl group adjacent to the oxadiazolone ring was often detrimental and that the distal 
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cyclopropane was beneficial for activity. These results will guide further exploration of 
this receptor.  
Introduction 
GPR55, a recently deorphanized, rhodopsin-like (class A) G protein-coupled 
receptor (GPCR), is a receptor for l-α-lysophosphatidylinositol (LPI, Figure 17) which 
serves as the endogenous agonist (GenBank entry NM 005683).1 Initial studies noted that 
a variety of CB1 and CB2 ligands bind to GPR552, 3 and more recent studies have 
focused on physiological roles for GPR55 in inflammatory pain,2 neuropathic pain,2 bone 
development,3 and the potential for activation of GPR55 being pro-carcinogenic.4,5,6,7,8 
Despite the important potential biological functions of GPR55, the research is limited by 
the lack of both potent and selective agonists and antagonists.9,10 
 
Figure 17. LPI and Lead Antagonists of GPR55.12 
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Based on a high-throughput, high-content screen of approximately 300,000 
compounds from the Molecular Libraries Probe Production Centers Network initiative,11 
a few molecular scaffolds were identified that had relatively good selectivity and potency 
as antagonists at GPR55. These structures were then docked into the inactive state model 
of GPR5512 to visualize the key features of the antagonists. Of the compounds that 
exhibited selective and moderate activity as antagonists at GPR55, three different 
structural families were identified as illustrated by ML191, ML192, and ML193 (Figure 
17). The docking of the structures in Figure 17 into the inactive state model of GPR55 
indicated a few important interactions as we previously reported.12 Briefly, the primary 
interaction was hydrogen bonding between the lysine at position 2.60(80)13 and the 
oxadiazolone carbonyl in ML191, the amide carbonyl in ML192, or an oxygen of the 
sulfonamide in ML193. The hypothesized interactions with K2.60(80) positioned the 
bottom aryl rings of all three structures, as represented in Figure 18, to maintain the 
toggle switch interaction between M3.36(105) and F6.48(239). The remaining 
interactions of the ligands presented in Figure 18 and GPR55 are primarily aromatic 
stacking with various residues. Specifically for ML191, the toluene ring attached to the 
cyclopropane stacks with F169 and the phenyl group attached to the oxadiazolone stacks 
with F6.55(246) and F3.33(102) (Figure 18). In addition to these interactions, moderate 
beneficial van der Waals interactions were identified between the oxadiazolone and both 
M7.39(274) and Y3.32(101). Since the interactions between ML191 and GPR55 centered 
on the three aromatic rings of ML191, compounds were desired that modified the 
electronics and sterics of these areas. Hence, the ML191 synthetic studies reported herein 
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were undertaken to explore the SAR of this oxadiazolone class of compounds. ML191 
was also chosen as the lead antagonist since there are very few structurally related 
compounds that could be purchased and screened compared to the available compounds 
for ML192 and ML193. 
 
Figure 18. (A) Docking and Key Interactions between ML191 and GPR55. ML191 
(Green) Has a Key H-bond Interaction with K2.60 (Pink). ML191 Also Has π-stacking or 
Other van der Waals Interactions with F169, F3.33, F6.55, M7.39, and Y3.32 (All 
Mustard). The Interactions with M7.39 and F6.55 Appear to Hinder the Rotation of 
M3.36 and F6.48 (Both Purple) Which Are Considered the Toggle Switch for GPR55. 
(B) Electrostatic Potential Map of ML191. This Figure is Adapted from Previously 
Published Work.12 
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Our synthetic approach to GPR55 antagonists was designed so that many different 
structures could be accessed to rapidly explore initial SAR, along with validating or 
modifying our current model (Figure 18).11 The synthesis begins with the coupling of a 
carboxylic acid to 4-piperidone by first forming the acid chloride (Scheme 1a; Figure 19). 
The different acids chosen, based on the initial hit, modify the electronics and sterics of 
this section of the molecule. Relative to ML191, compound 2a reduces the steric impact, 
2b increases the electron-density in the aromatic ring, and compounds 2c and 2d decrease 
the electron-density. Compounds 2e and 2f were selected to examine the influence of 
steric bulk at the position of the cyclopropane ring. The largest change in overall 
structure relates to the 1-naphthoic acid derivative (2f). Although the naphthalene ring is 
structurally different, this analogue can position the distal aromatic ring in a similar 
position as the phenyl rings of the other analogues since the bond angle for the Cα will be 
similar to that of the cyclopropane analogues, however, this structure is much flatter. 
 
Figure 19. Scheme 1a: Synthesis of Acylated Piperidones. 
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With a handful of acylated piperidones prepared, the final two steps first involved 
a reductive coupling of aryl hydrazides (3t–z) with the previously synthesized 
piperidones (2a–f) to yield hydrazides 4 (Scheme 2; Figure 20).14 These compounds were 
then cyclocarbonylated using triphosgene to yield oxadiazolones 5.15 The reductive 
coupling reactions proceeded smoothly but the products of that step were often unstable 
to silica gel chromatography. Therefore, the unpurified products were treated with 
triphosgene without further purification. This modification of the synthesis typically 
improved the yields of the final compounds (see Supplementary Data in Appendix A for 
individual yields). 
 
Figure 20. Scheme 2: Synthesis of GPR55 Antagonists. 
 
Similar to the cyclopropane starting materials (1a–f), the hydrazides (3t–z) were 
selected to probe the electronic and steric opportunities in the binding site. Based on the 
current model (Figure 18), the aromatic ring adjacent to the oxadiazolone is involved in 
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an interaction with M3.36(105) and F6.48(239). Additionally, the oxadiazolone 
contributes as the key interaction between the basic carbonyl oxygen with the ammonium 
of K2.60(80). Thus, electron rich aromatic rings adjacent to the oxadiazolone should 
make the carbonyl oxygen more basic and strengthen this interaction. 
A targeted exploration of the SAR of all six acids (1a–f) with hydrazide 3t and all 
seven hydrazides (3t–z) with acid 1a (Figure 19 and Table 1) was performed instead of 
synthesizing and exploring the biological activity of all 42 permutations of the six acids 
and seven hydrazides. Acid 1a and hydrazide 3t were chosen as the constants since these 
were the most simplified pieces consisting of an unsubstituted phenyl ring. 
Unfortunately, there were solubility issues with some of the compounds (e.g., 5bt and 
5bv), so additional combinations were required to elucidate the effect of the different 
areas of the scaffold. 
 
Table 1 
GPR55 Antagonist Activity of Compounds 
Entry, 
Compound 
 
R 
 
Ar 
IC50a  
(95% CI) 
1, 5at 
12 µM 
(3.9 - 36) 
2, 5au 
0.42 µM 
(0.075 - 2.4) 
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Table 1 
Cont. 
Entry, 
Compound 
 
R 
 
Ar 
IC50a  
(95% CI) 
3, 5av 
7.0 µM 
(0.47 - 100) 
5, 5bt insol.b 
6, 5bv insol.b 
7, 5bw 
1.8 µM 
(0.74 – 4.3) 
8, 5ct 
 
2.5 µM 
(1.3 – 5.0) 
9, 5dt 
 
0.64 µM 
(0.33 - 1.2) 
10, 5et 
  
0.77 µM 
(0.39 - 1.5) 
Note. IC50 values and 95% confidence intervals (CI) were determined by running the sample in triplicate 
versus a 6 μM concentration of LPI. bCompound was not completely soluble at the concentrations of the 
assay. 
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Compounds were initially screened via an image-based cell assay to identify 
antagonist activity. The rationale for using the β-arrestin recruitment assay was to provide 
a fair comparison of IC50 values since our initial report employed this assay.11,12 Briefly, 
U2OS cells overexpressing GPR55 and βarr2-GFP were exposed to LPI (6 μM; EC80) 
resulting in the recruitment of β-arrestin. Antagonist activity was evaluated by ligand-
mediated inhibition of LPI-induced receptor activation. This strategy quickly identified 
the compounds that had IC50 values higher than 15 μM which were excluded from further 
analysis (Figure 21). 
 
Figure 21. Analogues with Poor Activity (>15 μM). 
 
Concentration response curves were generated for compounds that were active at 
concentrations below 15 μM employing both the image-based β-arrestin recruitment 
assay and the DiscoveRx PathHunter® chemiluminescent β-arrestin complementation 
assay. In the DiscoveRx PathHunter® system, CHO-K1 cells stably expressing GPR55 
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(fused with a β-galactosidase enzyme fragment), and β-arrestin (fused to an N-terminal 
deletion mutant of β-galactosidase) were used to quantitate the inhibition of LPI-induced 
β-arrestin activity (Figure 22, Table 1). Hence, antagonist activity was evaluated through 
the use of two differential means of β-arrestin quantitation, in two different cellular 
backgrounds (see Supplemental information, Biological Assay). IC50 values were similar 
in both methodologies. 
 
Figure 22. Representative Images of Antagonist Screening. (A) 0.1 μM 5dt + LPI; (B) 
1.0 μM 5dt + LPI; (C) 10 μM 5dt + LPI; (D) 3 μM LPI; (E) 10 μM 5dt; (F) DMSO. 
 
Screening of the compounds allowed for a number of interesting SAR 
observations. First of all, pyridyl analogue 5au demonstrated that a pyridine ring would 
be beneficial for both c log P as well as increasing the potency (entry 2 versus entry 1). 
Electron-poor aryl groups next to the oxadiazolone were detrimental (Figure 21), but 
electron-rich groups were also not beneficial (entry 3). As discussed earlier, it was 
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anticipated that the more electron-rich aryl groups next to the oxadiazolone would be 
beneficial electronically, but the results obtained could be validated by the electron-
donating groups being larger and creating some detrimental steric interactions. 
It was found that electron-rich cyclopropylaryl groups had relatively good 
activities (entry 7), but also typically had solubility problems (entries 5 and 6). 
Fortunately, analogue 5bw was soluble, but the moderate activity illustrates that the p-
methoxy group is detrimental since the most closely related analogue (ML191, Figure 17) 
was more active and the electron-withdrawing p-chloro analogue (5dt) was even more 
active. Dichlorophenyl analogue 5ct had good activity, but was not as potent as compared 
to the monochloroaryl compound (entries 8 and 9) which could be justified based on the 
larger steric bulk of the second chlorine atom. Structure 5et with the dimethylcyclopropyl 
group was similarly active (entry 10) as compared to the parent compound, ML191 
(Figure 17) which is interesting since this compound adds more steric bulk to the 
cyclopropyl aryl section of the molecule, albeit in a slightly different location than 
analogue 5ct. It should be noted that analogue 5et is the only structure analyzed that is 
chiral. The synthesis of 5et was racemic and the model indicates that there are no major 
anticipated differences in activities between the two enantiomers. 
In conclusion, this letter presents initial SAR for piperidine-substituted 
oxadiazolone antagonists at GPR55, a recently deorphanized G protein-coupled receptor 
that lacks a potent and selective ligand of nanomolar potency. These data help to better 
define areas for improvement of this family of GPR55 antagonists since both halves of 
the molecule were independently modified. The activities spanned about two orders of 
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magnitude and will be used as a guide for future efforts which will be published in due 
time. 
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CHAPTER III 
 
BUILDING OF THE ACTIVE AND INACTIVE STATE MODELS OF GPR55 
 
Introduction 
 The previous GPR55 homology model (Evangelia et al.)1, was created using the 
crystal structure of the β2-adrenergic receptor (Protein Data Bank entry 2RH1)2 as a 
template. That model was later altered to reflect several structural elements that were 
observed in the recently crystallized structure of the CXCR4 receptor in its inactive 
state.3 The impetus for the current revision of the receptor originates from the pursuit of 
two goals: (a) A desire to explain new mutation results, suggesting that K2.60 and E3.29 
are crucial residues for binding in GPR55 and (b) The need to have an up-to-date model 
that reflects the high degree of sequence homology GPR55 shares with a logically chosen 
crystal structure template and that incorporates the structural information gleaned from 
both the agonist and antagonist ligands that have been synthesized thus far.  
            In the work discussed here, the Ballesteros-Weinstein numbering system for Class 
A GPCRs will be used.4 In this numbering system, the position of each residue is labeled 
by two numbers. The first (1 through 7) corresponds to the transmembrane helix (TMH) 
in which the residue is located. The number following the helix indicates the residue’s 
position relative to the most highly conserved residue (among Class A GPCRs) in that 
helix. The conserved residue in each helix being given the number .50 and residues 
before or after it are numbered accordingly. 
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Sequence alignments (Figure 23) have been compiled which compare GPR55 
with CB1, CB2, the h-ẟopioid receptor and other Class A GPCRs. These alignments 
allow for a more facile comparison of amino acid sequence similarities and deviations 
between receptors. The same highly conserved residues that have been used in the past to 
align the sequences of CB15-9 and CB210,11 to that of bovine rhodopsin were used as 
alignment guides for GPR55. These residues are the most highly conserved residues 
across Class A GPCRs: TMH1 - N1.50, TMH2 - D2.50, TMH3 - E/D3.49, R3.50, Y3.51 
(DRY motif), TMH4 - W4.50, TMH5 - P5.50, TMH6 - C6.47, W6.48, X (this residue 
varies), P6.50 (CWXP motif), and TMH7 - N7.49, P-7.50, X, X, Y7.53. Sequence 
patterns are easily identifiable on multiple sequence alignments and allow for easy 
comparison among residues in the transmembrane regions of different receptors. While 
GPR55 possesses some of the highly conserved .50 residues (N1.50, D2.50, W4.50 and 
P5.50) found in many GPCRs, there are a few notable differences. GPR55 has a 
conservative substitution (DRF) for the TMH3 E/DRY motif, a conservative substitution 
(SFLP) for the TMH6 CWXP motif, and a non-conservative substitution (DVFCY) for 
the THM7 NPXXY motif. Outside of the TMH region, GPR55 has an extracellular-1 
(EC-1) loop that is shorter than most (three residues versus the six found in β2-AR and 
Rhodopsin) and an EC-3 loop that is noticeably longer (fourteen residues long versus the 
five in β2-AR and the six residues in rhodopsin, CB1 and CB2). Based upon sequence 
alignments from the Reggio lab, the template chosen for the new GPR55 models was the 
ẟ-Opioid Receptor.12 See Figure 24. 
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Figure 23. GPCR Multi-Sequence Alignment. 
 
Figure 24. δ-Opioid Receptor. 
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Constructing the GPR55 R and GPR55 R* TMHs 
Updating the receptor models mandated an assessment of sequence-dictated 
conformational divergences of the GPR55 transmembrane helices (TMH) from the 
chosen 1.8 angstrom ẟ-opioid receptor crystallographic template. The Monte 
Carlo/simulated annealing technique CM13 was used to study the conformations of four 
GPR55 TMHs (TMHs 1, 5, 6, 7) with important sequence divergences from the DOR 
template. This technique allows for thorough exploration of conformations of TMHs 
containing helix deforming residues such as Proline, Glycine, Serine or Threonine. 
 
Figure 25. CM Output for Active-State GPR55 TMH6 Clustered, Showing F6.48. 
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Conformational Memories explores the low free energy conformations possible 
for a helix of interest using Monte Carlo simulated annealing. The CM method, 
developed by Guarnieri and Wilson13 and expanded by Guarnieri and Weinstein,14 was 
used originally to thoroughly explore the dihedral conformational space of a molecule, 
independent of the dihedral conformation of the initial molecular structure. The method 
has been expanded to allow the variation of bond angles in addition to dihedral angles.15 
CM combines Monte Carlo exploration of the dihedral angle space with simulated 
annealing (MC/SA) to determine the range of values in which each dihedral angle is 
capable of existing within a broad temperature range. In the CM calculations used to 
construct the GPR55 TMHs under consideration, the backbone dihedrals of each helix 
were set to the standard φ (-63°) and ψ (-41.6°) for transmembrane helices. The 
established protocol is then to allow all torsion angles to vary ±10°, and to allow a larger 
variation of ±50° in regions containing flexible series of residues.16 
The CM calculation is performed in two phases: an exploratory phase and a 
biased annealing phase. In the exploratory phase, a random walk is used to first identify 
the region of conformational space most probable for each torsion angle and bond angle. 
The initial temperature for each run was 3000 K with 50,000 Monte Carlo steps applied 
to each torsion or bond angle variation with step-wise cooling, over 18 steps, to a final 
temperature of 310 K. Each step consists of varying two dihedral angles and one bond 
angle chosen at random from the entire set of variable angles. The torsion angles and 
bond angles are randomly picked at each temperature and each move is accepted or 
rejected using the Metropolis Criterion (Figure 26).17  
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Figure 26. Metropolis Criterion. 
 
Accepted conformations in the Exploratory Phase are used to create “memories” 
of torsion angles and bond angles that were accepted (Figure 27). This information 
provides a map of the accessible conformational space of each TMH as a function of 
temperature. In the biased annealing phase, the only torsion angle and bond angle moves 
attempted are those that would keep the angle in the “populated conformational space” 
mapped at 310 K in the exploratory phase. The biased annealing phase for the 
calculations reported here began at 749.4 K with cooling to 310 K in 7 steps. 
 
Figure 27. Conformational Memory for S2.40 1 from GPR55. 
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One hundred eight structures were output at 310 K. The output from each TMH 
study was then superimposed on the corresponding template helix in the ẟ-Opioid receptor 
template from the intracellular (IC) end of the receptor up to the .50 residue. This particular 
superposition was to allow for examination of how CM represented the variation that could 
occur at the extracellular (EC) end of each TMH. The only exception to this superposition 
was TMH6 which had to be superimposed from the IC portion of the helix downward so 
as to represent the GPR55 R* “kicked out” region, occurring upon receptor activation, of 
the bottom of the helix. A helix was selected for inclusion in the revised GPR55 model that 
fit in the bundle with no van der Waals overlaps with residues on other TMHs.  
Extracellular and Intracellular Loops 
Extracellular and intracellular loops connecting all 7 TMHs were then added 
using MODELLER v8.2 26. MODELLER is a computer program used in producing 
homology models of protein tertiary structures.18 It employs a technique originating in 
nuclear magnetic resonance known as satisfaction of spatial restraints, by which a set of 
geometrical criteria are used to create a probability density function for the location of 
each atom in the protein.  
Energy minimizations were performed using Macromodel and the OPLS2005 all-
atom force field (version 9.8, Schrödinger, LLC, New York, NY). A distance-dependent 
dielectric, 8.0 Å extended non-bonded cutoff, 20.0 Å electrostatic cutoff, and 4.0 Å 
hydrogen bond cutoff were used. The minimization was performed in two stages. In the 
first stage, a harmonic constraint was placed on all the TMH backbone torsions (ϕ, ψ, and 
ω), with this constraint gradually reduced to zero in 500-step increments (using a total of 
56 
 
5000 steps to reach zero). In addition, a 500 kcal/mol harmonic constraint was placed on 
the backbone torsions of the loops. The minimization consisted of a conjugate gradient 
minimization using a distance-dependent dielectric, performed in 1000-step increments 
until the bundle reached the 0.05 kJ/mol gradient. In the second stage of the calculation, 
the TMH portion of the bundle was frozen, but the loops were allowed to relax. The 
generalized Born/surface area continuum solvation model for water as implemented in 
Macromodel was used. This stage of the calculation consisted of a Polak-Ribier 
conjugate gradient minimization in 1000-step increments until the bundle reached the 
0.05 kJ/mol gradient.  
Conformational Assessment of the Ligands 
A complete systematic conformational analysis of ligands (both agonists and 
antagonists) to be docked in the GPR55 models was performed, in parallel to the CM and 
prior to the docking of each ligand in its respective receptor, using ab initio Hartree-Fock 
calculations at the 6–31G* level as encoded in the Spartan molecular modeling program 
(Wavefunction, Inc., Irvine, CA). Specifically, HF 6–31G* 6-fold conformer searches 
were performed for all rotatable bonds within a molecule (Figure 28). In each conformer 
search, local energy minima were identified by rotation of a subject torsion angle through 
360° in 60° increments (6-fold search), followed by HF 6–31G* energy minimization of 
each rotamer generated. To calculate the difference in energy between the global 
minimum energy conformer of each compound and its final docked conformation, 
rotatable bonds in the global minimum energy conformer were driven to their 
corresponding value in the final docked conformation, and the single-point energy of the 
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resultant structure was calculated at the HF 6–31G* level. As an example of the output, 
the global minimum energy conformer of ML184 and the actual docked conformer are 
shown below superimposed on all heavy atoms (Figure 29). 
 
Figure 28. GPR55 Agonist ML184 with Two of Six Rotatable Bonds Indicated. 
 
Figure 29. GRPR55 Agonist ML184 Docked (Cyan) and Global Minimum (Copper) 
Conformations. 
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Docking of Ligands 
The lowest energy conformation of all ligands was used, unless otherwise noted, 
for all receptor docking studies. The Schrödinger module, Induced Fit, (Schrödinger Inc. 
Portland, OR) was used to explore possible binding conformations and receptor site 
interactions in the GPR55 R and R* models. The binding site of the receptor was defined 
by the area enclosed in a box with dimensions 26Å x 26Å x26Å (the default value).   
  Because the endogenous ligand, LPI, is negatively charged, it is likely that a 
positively charged amino is a primary interaction site for GPR55 ligands. The only 
positively charged amino acid in the binding pocket of the original model was K2.60 
(80). Recent K2.60A and E3.29A mutation studies suggest that both of these charged 
residues are crucial for ligand activation at GPR55 (M. Lingerfelt et al., manuscript 
submitted to Biochemistry). For this reason, both K2.60 (80) and E3.29A (98) were set as 
the center of the box and a hydrogen bond with K2.60 (80) was defined as a constraint. 
The two constraints (enclosing box and hydrogen bond) were used for both steps that 
Induced Fit Docking (IFD) performs.  
The initial receptor minimization that IFD implements in preparation for docking 
ligands was omitted because the receptor model had already been energy minimized. For 
the first Glide calculation, receptor and ligand Van der Waals radii were set to the default 
value of 0.50 and the number of maximum poses to be produced was also set to 40. 
During the Prime stage of the calculation, amino acids within 5.0Å of the ligand were 
refined to better accommodate the ligand. Since the GPR55 receptor is a transmembrane 
protein, an implicit membrane was used during the Prime refinement step. During the 
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second step, the actual docking of the ligand performed by the module GLIDE, the top 30 
poses produced by the first calculation were re-docked in the receptor. Docked poses that 
were within 40.0 kcal/mol of the absolute relative lowest one were kept.  
Ligand/Receptor Minimization 
To optimize the ligand/receptor interaction in the receptor/ligand complexes, each 
was minimized using Macromodel 9.1 (Schrödinger Inc.; Portland, OR). As described 
above in the section for bundle construction, 500 steps of Polak-Ribier conjugate gradient 
minimization using force field defined dielectric were performed. A harmonic constraint 
was placed on all the TMH backbone torsions (φ, ψ, and ω) to preserve the general shape 
of the helices during minimization. The sidechains of the TMH region, the loops and 
termini were allowed to relax. The Generalized Born/Surface Area (GB/SA) continuum 
solvation model for water as is implemented in Macromodel 9.1 was used for minimizing 
the loop regions. An 8.0Å nonbonded cutoff (updated every 10 steps), a 20.0Å 
electrostatic cutoff, and a 4.0Å hydrogen bond cutoff were used in each stage of the 
calculation. The transmembrane region and the docked ligand were then frozen while the 
loops were minimized. An example of the resultant ligand/receptor interaction energies 
for GPR55 agonist ML184 and the GPR55 R* bundle can be seen in Supplemental Table 
1 in Chapter IV. 
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This chapter was created by inserting the above cited paper, verbatim, with the 
following differences:  
 
1) Figures/Tables were re-rendered/resized to match dissertation global style.  
2) Page layout has been altered from published form to meet dissertation layout 
requirements (i.e. the use of 1 column vs. 2, etc.)  
 
Abstract 
GPR55 is a newly de-orphanized Class A GPCR that has been implicated in 
inflammatory pain, neuropathic pain, metabolic disorder, bone development, and cancer. 
Few potent GPR55 ligands have been identified to date.  This is largely due to an absence 
of information about salient features of GPR55, such as residues important for signaling 
and residues implicated in the GPR55 signaling cascade. The goal of the work reported 
here was to identify residues that are key for the signaling of the GPR55 endogenous 
ligand, l-α-lysophosphatidylinositol (LPI), as well as the signaling of the GPR55 agonist, 
ML184, (CID 2440433, 3-[4-(2,3-dimethylphenyl)piperazine-1-carbonyl]-N,N-dimethyl-
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4-pyrrolidin-1-ylbenzenesulfonamide). SRE and SRF luciferase assays were used as read-
outs for studying LPI and ML184 signaling at the GPR55 mutants. A GPR55 R* model 
based on the recent DOR crystal structure was used to interpret the resultant mutation 
data. Two residues were found to be crucial for agonist signaling at GPR55, K2.60 and 
E3.29, suggesting that these residues form the primary interaction site for ML184 and 
LPI at GPR55. Y3.32F, H(170)F and F6.55A/L mutation results suggested that these 
residues are part of the orthosteric binding site for ML184, while Y3.32L, M3.36A and 
F6.48A mutation results suggest the importance of a Y3.32/M3.36/F6.48 cluster in the 
GPR55 signaling cascade. C(10)A and C(260)A mutations suggest that these residues 
form a second disulfide bridge in the extracellular domain of GPR55, occluding ligand 
extracellular entry in the TMH1-TMH7 region of GPR55. Taken together, these results 
provide the first set of discrete information on residues important for LPI and ML184 
signaling and for GPR55 activation. This information should aid in the rational design of 
next generation GPR55 ligands and hopefully the creation of the first high affinity 
GPR55 radioligand, a tool that is sorely needed in the field. 
Introduction 
GPR55 [GenBank accession number NM005683] is a Class A G-protein coupled 
receptor (GPCR) that recognizes a sub-set of cannabinoid CB1 and CB2 ligands, 
suggesting that GPR55 may be a cannabinoid receptor. 1 Subsequently, l-α-
lysophosphatidylinositol1-2 was reported to be the endogenous ligand of GPR55. GPR55 
has been found to be implicated in inflammatory pain, neuropathic pain, metabolic 
disorder, bone development, and cancer,3 indicating the real potential of GPR55 ligands 
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as therapeutics. In search of more potent GPR55 ligands and in collaboration with the 
Sanford-Burnham Institute, we performed high throughput screens for GPR55 agonists 
and antagonists using the NIH library of 300,000 compounds and identified several novel 
GPR55 chemotypes for each.4 One of these compounds from the agonist screen is 
ML184, (CID 2440433, 3-[4-(2,3-dimethylphenyl) piperazine-1-carbonyl]-N,N-dimethyl-
4-pyrrol-idin-1-ylbenzenesulfonamide)5 (EC50=263nM). However, despite these ligand 
development efforts, the best GPR55 ligands (like ML184) remain active at sub-
micromolar concentrations, concentrations not low enough for the development of a 
GPR55 radioligand.  
To address this situation, we reasoned that knowledge of GPR55 structure, 
particularly binding pocket residues important for ligand signaling and those involved in 
the receptor activation would greatly aid rational GPR55 drug design approaches. To this 
end, we report here a GPR55 mutation study guided and analysed using a GPR55 R* 
model based on the recent delta opioid receptor (DOR) crystal structure. This study 
identifies multiple residues important for ML184 signaling and for GPR55 activation. 
Results 
Biological Evaluation 
SRE responses of mutant and wild-type GPR55 receptors. HEK293 cells 
transiently transfected with both pGL4.33 [luc2P/SRE/Hygro] and each of the mutants, as 
well as, WT were made to assess agonist-induced receptor activation of SRE. The SRE 
assay assesses the contribution of MAPK/ERK signaling pathway for GPR55 activity. 
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We found that the WT GPR55 has an EC50 value of 56 nM for the agonist ML184 
(Figure 30 and Table 2). 
 
 
 
 
Figure 30. SRE Responses Induced by ML184 in GPR55 Wild Type and Mutant 
Transfected Cells. (A) WT GPR55, Y3.32F and Y3.32L. (B) WT GPR55, F6.55A and 
F6.55L. (C) WT GPR55, Q6.58M and C(10)A. (D) WT GPR55, Q7.36A and Q7.36N. 
(E) WT GPR55, H(170)F and C(260)A. (F) WT GPR55, M3.36A, F6.48A, K2.60A, 
E3.29A and E3.29L. 
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Table 2 
ML184 Induced SRE Responses of Wild-type and Mutant Transfected Cells 
ML184 EC50 (nM) CI (nM) Fold/WT 
WT 56 24 to 133 - 
Y3.32F 1659 670 to 4110 30 
Y3.32L 9514 718 to 126100 170 
F6.55A 840 345 to 2045 15 
F6.55L 5131 1034 to 25460 92 
Q6.58M 72 22 to 237 1 
C(10)A 635 197 to 2044 11 
H(170)F 341 158 to 734 6 
C(260)A 657 222 to 1941 12 
Q7.36A 230 57 to 920 4 
Q7.36N 154 69 to 342 3 
M3.36A 900 290 to 2790 16 
F6.48A 514 266 to 993 9 
K2.60A NO response - - 
E3.29A >30000 very wide - 
E3.29L >30000 Very wide - 
Note. From n > 3 experiments  
 
We determined that the EC50 value did not change regardless of the level of 
receptor expression (See Figure S1 in Supporting Information). Mutants Y3.32F and 
Y3.32L showed right shifted SRE response curves with EC50’s higher than WT (Figure 
30 A). The mutants F6.55A and F6.55L induced a similar SRE response to ML184 with 
right shifted curves. The Q6.58M curve was almost identical to that of WT indicating this 
mutant is not important to GPR55 receptor function. The mutant C(10)A showed an 
increased  EC50 value (636 nM). Very similarly, the mutant C(260)A induced an 
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increased EC50 value (657 nM), suggesting the existence of a disulfide bridge (see 
below). Q7.36A and Q7.36N showed similar responses to WT indicating this amino acid 
is not critical for agonist induced GPR55 receptor activation. The response curve of 
H(170)F only showed a slight difference from that of WT. Mutant M3.36A, F6.48A, 
E3.29A and E3.29L all showed increased EC50 values. E3.29A and E3.29L showed very 
little responses. Among all the mutants, K2.60A did not show any response in the SRE 
assay indicating that K2.60A rendered the GPR55 receptor non- functional. 
In addition to the agonist ML184, the endogenous ligand (LPI) was used in the 
SRE assay for all the mutants (Figure 31). K2.60A did not show any LPI induced 
responses compared with WT. E3.29A and E3.29L showed a slight response at high 
concentration of LPI. F6.55A, F6.55L, Q6.58M, Q7.36A and Q7.36N all showed similar 
curves as to WT. Y3.32F, Y3.32L, C(10)A, H(170)F, C(260)A, M3.36A and F6.48A 
showed right shifted curve compared with WT. The LPI induced SRE response did not 
reach plateau for all the constructs including WT GPR55, thus no EC50 value was 
calculated.      
SRF responses of mutant and wild-type GPR55 receptors. In addition to the 
SRE assay, the SRF assay was used to investigate another signaling pathway of GPR55. 
The SRF response is an indicator of G12-RhoA pathway activation which GPR55 has 
been reported to induce.6 The study of two distinct signaling pathways of GPR55 
broadens the understanding of effects of these mutants on GPR55 function. Thus, the 
SRF assay was used to test GPR55 mutants in addition to the SRE assay (Figure 32 and 
Figure 33). 
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Figure 31. SRE Responses Induced by LPI in GPR55 Wild Type and Mutant Transfected 
Cells. (A) WT GPR55, Y3.32F and Y3.32L. (B) WT GPR55, F6.55A and F6.55L. (C) 
WT GPR55, Q6.58M and C(10)A. (D) WT GPR55, Q7.36A and Q7.36N. (E) WT 
GPR55, H(170)F and C(260)A. (F) WT GPR55, E3.29A and E3.29L. (G) WT GPR55 
and M3.36A. (H) WT GPR55, F6.48A and K2.60A. 
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Figure 32. SRF Responses Induced by ML184 in GPR55 Wild Type and Mutant 
Transfected Cells. (A) WT GPR55, Y3.32F and Y3.32L. (B) WT GPR55, F6.55A and 
F6.55L. (C) WT GPR55, C(10)A and C(260)A. (D) WT GPR55, M3.36A, F6.48A, 
K2.60A, E3.29A and E3.29L. 
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Figure 33. SRF Responses Induced by LPI in GPR55 Wild Type and Mutant Transfected 
Cells. (A) WT GPR55, Y3.32F and Y3.32L. (B) WT GPR55, F6.55A and F6.55L. (C) 
WT GPR55, C(10)A and C(260)A. (D) WT GPR55, E3.29A and E3.29L. (E) WT GPR55 
and M3.36A. (F) WT GPR55, F6.48A, K2.60A. 
C D 
E F 
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Y3.32F and Y3.32L showed right shifted curves compared with WT. Y3.32L had 
a higher EC50 value (864 µM; Figure 32). Similar to the SRE assay, the F6.55A and 
F6.55L had higher EC50 values than WT (Figure 32, Table 3). Both C(10)A and C(260)A 
showed less response than WT. M3.36A, F6.48A, E3.29A and E3.29L all behaved in the 
SRF assay similar to in the SRE assay with reduced responses. K2.60A was not able to 
induce any response in the SRF assay similar to its inactivity in the SRE assay.  
 
Table 3 
ML184 Induced SRF Responses of Wild-type and Mutant Transfected Cells 
ML184 EC50 (nM) CI (nM) Fold/WT 
WT 33 15 to 75 - 
Y3.32F 851 449 to 1615 26 
Y3.32L 864000 very wide 26182 
F6.55A 550 338 to 893 17 
F6.55L 10500 4663 to 23630 318 
C(10)A 554 254 to 1206 17 
C(260)A 363 201 to 656 11 
M3.36A 2044 1415 to 2952 62 
F6.48A 335 177 to 633 10 
K2.60A NO response - - 
E3.29A > 30000 very wide - 
E3.29L > 30000 very wide - 
Note. n ≥ 3 experiments. 
 
Molecular Modeling 
No x-ray crystal structure for GPR55 has been reported. For this reason, a GPR55 
activated state (R*) model based upon the crystal structure of the delta-opioid receptor 
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(DOR) was used to interpret the mutation results reported here.7 Glide docking studies in 
this model focused on ML184. These studies were used to identify a docking site for 
ML184 in the GPR55 R* model that involves residues on TMHs2-3-5-6 and the EC-2 
loop. 
 
Figure 34. GPR55 Agonist ML184, Numbered to Show Torsional Angles Varied for 
Conformational Analysis. 
 
Primary interactions for agonist signaling. 
ML184 docked into the GPR55 R* bundle. Figure 35 describes the ML184 
binding site identified by Glide. Figure 35 A shows all hydrogen bonding interactions for 
ML184 at GPR55. Here, the ML184 sulfonamide oxygen hydrogen bonds directly with 
K2.60 (H bond (N-O) distance, 2.8 Å; (N-H—O) angle, 174). H(170) in the EC-2 loop 
also forms a hydrogen bond with an ML184 sulfonamide oxygen (H bond (N-O) 
distance, 2.8 Å ; (N-H—O) angle, 150). Y3.32 forms a hydrogen bond with the ML184 
carboxamide oxygen (H bond (N-O) distance, 2.8 Å; (N-H—O) angle, 163).  
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(A) 
 
(B) 
Figure 35. All Hydrogen and Aromatic Stacking Interactions for ML 184 at GPR55. (A) 
This Figure Shows All Hydrogen Bonding Interactions for ML184 at GPR55. The View 
is Looking from TMHs 4 and 5 towards TMH7. Hydrogen Bonding is Shown with 
Dotted Yellow Lines. (B) This Figure Shows All Aromatic Stacking Interactions for 
ML184 at GPR55. The View is Looking from TMH 4 towards TMH6. Aromatic 
Stacking Interactions are Shown with Light Blue Dotted Lines between Ring Centroids. 
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In addition to hydrogen bonding, ML184 also has aromatic stacking interactions 
in its binding site. Figure 35 B shows all of these aromatic stacking interactions. Y3.32 
and F3.33 form aromatic stacks with the ML184 benzene ring proximal to the ML184 
sulfonamide moiety (Y3.32 ring centroid to centroid distance 5.6 Å; angle 70); (F3.33 
ring centroid to centroid distance 6.5 Å; angle 47). F6.55 forms an aromatic stacking 
interaction with the distal, dimethyl-phenyl ring of ML184 (ring centroid to centroid 
distance 5.4 Å; angle 88), while F5.39 and F5.47 also form aromatic stacks with the 
central ML184 aromatic ring (F5.39 ring centroid to centroid distance 5.3 Å: angle 70; 
F5.47 ring centroid to centroid distance 4.5 Å: angle 41).  
M7.39 is engaged in a Met-aromatic ring interaction with the central benzene of 
ML184 (Distances to central benzene ring centroid from M7.39 sidechain atoms CG 5.1 
Å, SD 5.3 Å, CE 4.4 Å) (see Figure 36 A). 8 In this orientation, the sulfur points up, with 
adjacent carbons pointing down towards phenyl ring carbons on ML184. ML184 also has 
an indirect interaction with E3.29, as this residue holds K2.60 (with which ML184 has a 
direct hydrogen bond) in a salt bridge that directs K2.60 towards the ML184 binding site 
(see Figure 36 B). The ML184 conformer docked here is 1.91 kcal/mol above the ML184 
global minimum. 
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(A) 
 
(B) 
Figure 36. (A) M7.39 is Engaged in a Met-aromatic Ring Interaction With the Central 
Benzene of ML184.8 In This Orientation, the Sulfur Points Up, with Adjacent Carbons 
Pointing Down Towards Phenyl Ring Carbons on ML184. (B) Although There is no 
Direct Interaction Between ML184 and E3.29 in the Current Model, Modeling Suggests 
That E3.29 Forms a Salt Bridge with K2.60. This Salt Bridge Positions K2.60 for 
Interaction with ML184. The View Here is From TMH6 Looking Towards TMH2/3.
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Toggle switch residues. GPR55 shares with the P2Y129 and hPAR-110 receptors, 
a Y/F3.32-M3.36-F6.48 cluster of residues that likely acts as the toggle switch for 
activation of GPR55. Figure 37 illustrates these toggle switch residues contoured at their 
Van der Waals radii in the inactive (R) and the activated (R*) state.  
 
Figure 37. Positions of the Toggle Switch Residues Y3.32, M3.36, and F6.48 (Contoured 
at Their van der Waals Radii) in the GPR55 R and R* Models. Additional Aromatic 
Residues in the Region of the Toggle Switch Help Stabilize the Cluster of Residues. 
These are F3.33 and Y3.37. 
 
Inactive state. In the inactive state (Figure 37 A), Y3.32 (1= 178°) sits 
extracellular to M3.36 (1= -170), maintaining Van der Waals interactions with M3.36. 
M3.36 (1= -170°) is stacked over F6.48 (1= -90°). M3.36 also has a methione/aromatic 
ring interaction with F6.48 (Distances to F6.48 benzene ring centroid from M3.36 
sidechain atoms CG 3.6 Å, SD 4.6 Å, CE 3.8 Å).8 Additional aromatic residues in the 
A B
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region of the toggle switch help stabilize the cluster of residues. These are F3.33  
(1= -74°) and Y3.37 (1= -57°).  
Agonist activated state. ML184 binding causes Y3.32 to change conformations 
(1= 178 to 1= -157 ), because Y3.32 is a direct ligand binding site residue. Figure 37 
B illustrates that the movement of Y3.32 frees M3.36 to undergo a conformational 
change (1 = -170° trans to 1= -75° g+), which then allows F6.48 to undergo its (1 =  
-90 g+ to 1 = -177° trans) conformational change. The F6.48 conformational change 
causes flexing in the SFXP hinge region of GPR55, straightening TMH6 and breaking the 
ionic lock (R3.50/Q6.30) producing an opening at the intracellular end of GPR55 for G 
protein coupling. F3.33 (1 = -81°) and Y3.37 (1 = -55°) remain members of the 
extended cluster. Figure 38 illustrates the position of ML184 to the extended toggle 
switch residues in the GPR55 activated state.  
Disulfide bridge residues. As described in the Methods section, the high degree 
of sequence homology between GPR55 and the CXCR4 receptor,11 particularly in the EC 
regions, dictated several modifications to our initial set of GPR55 models.12 These were 
(1) the introduction of EC helical extensions on TMH5-7 of GPR55; (2) the introduction 
of a β sheet motif into the EC-2 loop in GPR55; and (3) the introduction of a disulfide 
bridge between Cys(10) in the N-terminus and Cys(260) in the EC-3 loop near the top of 
TMH7.13 In the current paper, we tested the importance of a Cys(10)-Cys(260) disulfide 
bridge via single point mutations. Figure 39 illustrates the extracellular end of the 
receptor and the disulfide bridge between N-terminal C(10) and C(260) at the EC end of 
TMH7. 
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Figure 38. Position of ML184 Relative to the Extended Toggle Switch Residues in the 
GPR55 Activated State. ML184 (Contoured at its Van der Waals Radii) is Positioned 
above Y3.32 and Interacts Directly with it. The Movement of Y3.32 for This ML184 
Interaction, Permits M3.36 (1 trans to g+) and,  in Turn, F6.48 (1 g+ to trans) to Change 
to Their R* Conformations. 
 
 
Figure 39. The Extracellular End of the Receptor and the Disulfide Bridge Between N-
Terminal C(10) and C(260) at the EC End of TMH7. 
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Binding pocket position. Figure 40 illustrates the positions of Q6.58 and Q7.36 
relative to the ML184 binding site.  These residues are positioned relatively high on the 
EC end of TMHs 6 and 7 and above the ML184 binding pocket in our current GPR55 R* 
model. In our first GPR55 model, Q6.58 was near the nitrogen in the pendant five 
membered ring of ML184 and able to form a hydrogen bonding interaction with this 
nitrogen.14 As discussed in the next section, mutation results suggested that Q6.58 and 
Q7.36 do not interact with ML184. This necessitated a re-orientation of ML184 in the 
binding pocket in the current model. 
 
Figure 40. Positions of Q6.58 and Q7.36 Relative to the ML184 Binding Site. Both 
Residues are Clearly Above the ML184 Binding Site. 
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Discussion 
Ml184 Docked into the GPR55R* Bundle 
When one begins the characterization of the ligand binding pocket in a newly de-
orphanized receptor, like GPR55, mutation studies are crucial to understanding the 
binding pocket. Our original GPR55 models (R and R*) were based on a beta-2-
adrenergic receptor template.12-13 In this model, we docked ML184 so that the ligand 
piperazine and di-methyl phenyl ring segment was vertical in the binding pocket, while 
the rest of the ligand occupied a horizontal space near the extracellular loops. Mutation 
results reported here clearly necessitate that a reorientation of ML184 occur in the 
binding pocket. In the refined model reported here, we also took advantage of crystal 
structures that were unavailable at the time of the original model creation and found that 
the delta-opioid receptor (DOR) crystal structure7 was a more appropriate template for 
the next generation model. The DOR, for example has a PRO at position 4.59, as does 
GPR55. The beta-2-adrenergic receptor, on the other hand, has a PRO shifted by one 
residue to 4.60. In addition, the DOR has the same toggle switch partner as GPR55, 
M3.36. 
Ligand Interactions within the Binding Crevice 
As predicted by previous studies conducted on the GPR55 receptor in the Reggio 
lab, the current model has a crucial hydrogen bonding interaction between ML184 and 
K2.60 on TMH 2 (see Figure 35A or 35B) that results in the strongest ligand Interaction 
Energy (-9.4 kcal/mol) of any residue in the GPR55 R* bundle (see Table S-1 in 
Appendix B). A strong hydrogen bond between the electronegative sulfonamide and the 
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positive lysine is consistent with the experimental results that show a complete loss of 
signaling upon the K2.60 mutation to an alanine (see Tables 2 and 3).  
Mutation of E3.29 to either an alanine or a leucine resulted in a profound 
reduction of receptor signaling as well. Though there is no direct interaction between 
ML184 and E3.29 in the current model, modelling suggests that E3.29 forms a salt bridge 
with K2.60 (see Figure 36 B). This salt bridge positions K2.60 for interaction with 
ML184. The loss of this residue’s directing capability for K2.60 via the E3.29/A/L 
mutations effectively make K2.60 less available in the binding pocket, leading to a 
considerable loss of function. 
At the ML184 binding site, the EC-2 loop residue, H(170), serves as a hydrogen 
bond donor to the ML184 sulfonamide oxygen (see Figure 35 A). The Interaction Energy 
for ML184 with H(170) is -3.5 kcal/mol (see Table S-1 in Appendix B). Simultaneously, 
the sulfonamide oxygen also receives a hydrogen bond from K2.60. Because hydrogen 
bonding is stronger when the donating residue is charged, the H170 hydrogen bond with 
ML184 is weaker (-3.5 kcal/mol) than that with K2.60 (-9.1 kcal/mol) (see Table S-1 in 
Appendix B). The pKa of histidine is 6.0. At physiological pH, about 10% of histidine 
residues are protonated. We assume here that H(170) is uncharged. An H(170)F mutation 
removes the hydrogen bonding ability of residue 170, but not its ability to form aromatic 
interactions. Mutation of H(170) to a phenylalanine resulted in a 6-fold reduction in SRE 
responses (see Table 2). The magnitude of the effect upon mutation is consistent with the 
loss of a hydrogen bond. In addition, the fact that H(170) mutation affected ML184’s 
signaling suggests indirectly that there is also a C(168)/C3.25 disulfide bond in GPR55. 
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This bond requires that the EC-2 loop extend over to TMH3 to link with C3.25 and 
therefore is responsible for the H(170) location in the GPR55 R* model. In addition, 
inspection of GPCR crystal structures that contain the analogous disulfide bridges reveal 
that the second residue after the disulfide bridge typically points down into the binding 
crevice. H(170) is the second residue after the C(168)/C3.25 disulfide bridge. 
Y3.32 serves two functions in GPR55. It is a binding site residue (see Figure 35 A 
and B) and also part of the extended toggle switch for GPR55 activation (see Figure 37). 
A stepwise loss of function is seen when Y3.32 is first mutated to a phenylalanine (30-
fold loss, see Table 2) and then a leucine (170-fold loss, see Table 2). At the ML184 
binding site, Y3.32 donates a hydrogen bond to the ML184 carboxamide oxygen (Figure 
35 A) and forms an aromatic stacking interaction with the ML184 central benzene ring 
(Figure 35 B) proximal to the ML184 sulfonamide moiety. The first mutation, Y3.32F, 
removes the residue’s potential to donate a hydrogen bond. The magnitude of the effect 
(30-fold loss) is consistent with Y3.32 serving as the lone hydrogen bond donor to 
ML184 in this region. The second mutation, Y3.32L, removes both hydrogen bonding 
and aromatic stacking interactions from the ML184 binding site at this position. The 170-
fold reduction in EC50 (see Table 2) is consistent with the loss of two important 
interactions for ML184. Y3.32F mutation results are also consistent with Y3.32’s 
participation in the extended toggle switch region in GPR55, as loss of aromaticity at 
3.32 in the Y3.32L mutant should have a profound effect on signaling (170-fold 
reduction in EC50; see Table 2). 
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The current model of GPR55 places F6.55 facing inward towards the binding 
crevice. This residue forms an aromatic stacking interaction with the distal, dimethyl-
phenyl ring of ML184 (Figure 35 B; Interaction Energy = -5.1 kcal/mol; see Table S-1 in 
Appendix B). The F6.55A mutation resulted in a 15-fold loss in EC50 for ML184, 
consistent with the loss of this aromatic stacking interaction. The F6.55L resulted in an 
even larger loss in EC50 (92-fold). This mutation not only removes an aromatic stacking 
interaction, but also causes crowding in the ML-84 binding pocket. This crowding causes 
ML184 to shift position and the net result would be reduced binding site interactions. The 
92-fold loss in EC50 is consistent with such an alteration.  
The x-ray crystal structure of the beta-1-adrenergic receptor complexed with Gs 
protein shows that TMH6 has straightened by flexing its proline kink at P6.50.15 This 
conformational change also impacts binding pocket residues. W6.48 has been shown to 
change its conformational state within the binding pocket upon receptor activation (1 g+ 
 trans). In the inactive state, W6.48 is typically held in its 1=g+ conformation by 
another binding pocket residue. Together, this pair of residues is known as the “toggle 
switch.”16 In the GPR55 activated state model reported here, Y3.32, M3.36 and F6.48 
form an extended toggle switch (see Figure 37), with additional interactions from F3.33 
and Y3.37. The mutation effects of Y3.32 are discussed above in the context of their 
effects on the ML184 binding pocket interactions and upon signaling. For both the SRE 
and SRF readouts used here, mutation of M3.36 to alanine had a significant impact on 
signaling (16-fold, 62-fold). Mutation of the toggle switch residues M3.36 and F6.48 
resulted in increased EC50 values, but these mutants were able to ultimately reach SRE 
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induction comparable to wild-type. As ML184 is a GPR55 agonist, it is expected that its 
position in the bundle would not cause it to interfere with the receptor’s ability to 
activate. This is verified by the experimental data and is what is observed in the current 
ligand receptor complex. 
 Class A GPCRs typically have a disulfide bridge between a residue in the EC-2 
loop and Cys3.25 near the top of TMH3. The sequence of GPR55 suggests that it likely 
has this disulfide bridge as well. Mutation studies of these Cys residues typically result in 
loss of function as the EC-2 – C3.25 disulfide bridge is important for binding pocket 
structure.17 The CXCR411,18 and CCR519 crystal structures reveal the existence of a 
second disulfide bridge that links the N terminus of the receptor to the EC end of TMH7, 
forming what has been called the fourth EC loop.19 This loop has been proposed to shape 
the entrance of the ligand-binding pocket and to add rigidity to the overall surface of the 
receptor.19 The sequences of ~30% of Class A GPCRs contain such Cys residues, 
including the lysophospholipid (LPA), bradykinin (B1-2), endothelin (ETA-B), 
melanocortin (MC1-5), serotonin (5-HT), purinergic (P2Y), and orphan receptors, such as 
GPR55. The structure of one of the latest resolved rhodopsin-like receptors, P2Y12, 
revealed the presence of such an EC-4 loop;9 however, the conservation of these residues 
does not necessarily imply the formation of a EC-4 loop (see crystal structures of 
dopamine D320 and serotonin, 5HT1B21 receptors). Because the GPR55 sequence 
suggests the presence of an EC-4 loop, this second disulfide bridge was incorporated into 
our GPR55 model and was tested via C(10)A and C(260)A mutations here. Results 
reported here show that each mutation impacts ML184 activation of GPR55, although 
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these mutations are not devastating (11-fold for C(10)A; 12-fold for C(260)A). We have 
taken these results as evidence that this disulfide bridge is present in GPR55 and have 
retained this bridge in our model (see Figure 39). It should be noted that the EC-4 loop 
may have larger effects on GPR55 agonists other than ML184, as it has been proposed 
that this fourth loop shapes the entrance of the ligand-binding pocket.19 
 Q6.58 and Q7.36 are located at the extreme EC ends of TMH6 and TMH7 (see 
Figure 40). In our first GPR55 model, Q6.58 was near the nitrogen in the pendant five 
membered ring of ML184 and able to form a hydrogen bonding interaction with this 
nitrogen.12 A Q6.58M mutation should have resulted in the loss of this hydrogen bond 
and a significant reduction in ML184 EC50. However, at the Q6.58M/A mutations, 
ML184 retained WT signaling. This result is a key result from a modelling perspective 
because it clearly suggested that a different binding mode for ML184 should be sought.  
Also in our previous GPR55 R model, Q7.36 interacted simultaneously with 
K2.60 and with antagonist, ML192.13 The re-orientation of ML184 dictated by the 
Q6.58M/A mutations dictated that Q7.36 should have no ligand interactions. Consistent 
with this result, experimental data reported here shows that at both the Q7.36A and 
Q7.36N mutant, ML184 retains WT signaling.  
Quite recently, additional synthetic ligands, as well as another endogenous agonist 
for GPR55 have been described.22 The synthetic ligands employed our previous model as 
a guide for ligand design. The mutation results reported here will be important for the 
design of more potent and efficacious agonists for GPR55. 
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Conclusions 
Results reported here identify key GPR55 residues that are important for agonist 
signaling, as well as residues implicated in the agonist activated signaling cascade. Two 
residues crucial for ML184 signaling at GPR55 are K2.60 and E3.29. Three additional 
residues, Y3.32, H(170) and F6.55, are important for ML184 signaling. Further, results 
suggest that a cluster of residues, F3.32/M3.36/F6.48 serves as the toggle switch for 
activation of GPR55. GPR55 also likely possesses, a second disulfide bridge that links 
the N terminus of the receptor to the EC end of TMH7. This loop has been called the 
fourth EC loop.19 All of these results provide, for the first time, structural information 
that should aid in the rational design of next generation GPR55 ligands. It is hoped that 
this will lead to a high affinity GPR55 radioligand, a tool that is sorely needed in the 
field. 
Experimental Section 
Material and Reagents 
Soy LPI (purchased from Sigma-Aldrich), and ML184 (MolPort) were dissolved 
in dimethyl sulfoxide to a concentration of 10 mM. The SRE reporter, 
pGL4.33[luc2P/SRE/Hygro] and the SRF-RE reporter, pGL4.34[luc2P/SRF-RE/Hygro] 
were from Promega. 
Mutagenesis and Cell Culture 
The M3.36A, F6.48A, K2.60A, E3.29A, E3.29L, Y3.32F, Y3.32L, F6.55A, 
F6.55L, Q6.58M, C(10)A, H(170)F, C(260)A, Q7.36A and Q7.36N  mutants of the 
human GPR55 in the vector pcDNA3 were constructed using the QuikChange site-
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directed mutagenesis kit (Stratagene). DNA sequencing subsequently confirmed the 
presence of the desired mutation only.  
Serum Response Element (SRE) and Serum Response Factor (SRF) Assay 
HEK293 cells were transiently transfected with GPR55 and pGL4.33 
[luc2P/SRE/Hygro] or pGL4.34 [luc2P/SRF-RE/Hygro] vector reporter plasmids using 
Lipofectamine 2000 as described by the manufacturer (Invitrogen). Transfected HEK293 
cells were seeded (60,000 cells per well) in 96-well plates. Five hours later, medium was 
changed to 1% FBS/DMEM. Cells were incubated overnight. The next day cells were 
treated with ligands for 5 h in serum-free DMEM medium at 37°C. After treatment, cells 
were lysed by 1X lysis buffer for 10 min at room temperature. Plates were read to record 
bioluminescent light immediately after the injection of 40µl Luciferin (≥250µM) per 
well. Luminescence was measured in an Envision 2104 multilabel Reader (PerkinElmer). 
Luminescence values are given as relative light units. Concentration-effect curves for 
agonist-mediated receptor activation were analyzed by nonlinear regression techniques 
using GraphPad Prism 5.0 software (GraphPad) and data were fitted to sigmoidal dose-
response curves to obtain EC50 values. 
Modeling 
Amino acid numbering system. The amino acid numbering system used here is 
the Ballesteros-Weinstein numbering system23 in which the most highly conserved 
residue across Class A GPCRs in each TMH is assigned a number .50.  This number is 
preceded by the TMH number and can be followed by the absolute sequence number in 
parentheses. For example, the most highly conserved residue in TMH4 is W4.50. For 
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GPR55, this residue is W4.50(146). The residue preceding this residue is I4.49(145) and 
the residue following it is V4.51(147). Loop residues in this system are identified by their 
absolute sequence numbers only. 
Modeling of hGPR55 active-state bundle (GPR55 R*) using GPCR x-ray 
crystallography data. The model of the activated form of GPR55 (GPR55 R*) described 
in the current work was created using the 1.8 Å crystal structure of the human delta 
opioid receptor (hDOR, PDB id: 4N6H) as a template.7 Transmembrane regions of 
GPR55 vs. hDOR in which the placement of prolines differed (GPR55 transmembrane 
helices (TMHs) 1, 5, 6 and 7) were explored using the Conformational Memories (CM) 
method described below.24 
 Conformational Memories (CM) Method for Calculating TMH Conformation 
The CM method uses multiple Monte Carlo/simulated annealing random walks 
employing the CHARMM force field. Backbone φ and ψ torsions in regions of interest (i 
to i-4 of a proline) were allowed to vary +/- 50°, while all other backbone torsion angles 
were allowed to vary +/- 10°. Side chain torsions were allowed to vary +/- 180°. All bond 
angles were allowed to vary +/- 8° except for C-S-C angles that were allowed to vary +/- 
15°. A minimum set of 108 conformers was generated for each GPR55 helix, 
independently, in a distance dependent dielectric at 310 K.  
TMH1 in GPR55 has a Pro at position 1.41 not found in DOR. An ideal helix (φ= 
-62.9º, and ψ = -41.6°) with the GPR55 sequence was built, and the region containing the 
proline and 4 residues prior to the Pro (i to i-4, A1.37 - P1.41) was varied using CM.  
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TMH5 in GPR55 has two prolines, the highly conserved P5.50 and an additional 
one at position 5.41. TMH5 of the DOR crystal structure was mutated to the GPR55 
sequence and the backbone dihedrals from P5.41 to K5.37 were varied to explore the 
possible conformations caused by this second, proline. 
TMH6 in GPR55 has a conservative SFXP substitution in place of the highly 
conserved Class A CWXP motif. Biophysical studies have indicated that there is a salt 
bridge, or ionic lock (between R3.50 near the intracellular (IC) end of TMH3 and 
D/E6.30 at the IC end of TMH6), common to all Class A GPCRs that is broken upon 
activation. The breaking of this ionic lock allows TMH6 to straighten, moving its 
intracellular (IC) end away from the TMH bundle.25 For this reason, it was crucial to 
explore the conformational space of GPR55 TMH6 which has a glutamine (Q) at position 
6.30 in place of a typical aspartic (D) or glutamic (E) acid. The GPR55 TMH6 sequence 
was built, using the ideal helix values (φ= -62.9º, and ψ = -41.6º) and the i to i-4 region 
around the Pro (P6.50-V6.46) was varied using CM.  
TMH7 in GPR55 lacks the highly conserved Class A GPCR NPXXY motif 
having instead a DVXXY sequence. Traditionally the NPXXY motif influences the 
conformation of TMH7 and places Y7.53 in the correct position to interact with F7.60 on 
Helix 8 (Hx8, a short intracellular extension of TMH7 that lies usually parallel to the cell 
membrane). For receptors that possess an NPXXY motif, we have typically designated 
the backbone region of P7.50- X7.46 region as variable. For GPR55 TMH7, an ideal 
helix (φ= -62.9º, and ψ = -41.6º) was built and the i to i-4 region in which there is 
normally a Pro (V7.50 - C7.46) was varied using CM. 
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Construction of the GPR55 Active-state Bundle 
Transmembrane helices 2, 3 and 4 of the DOR were mutated to the corresponding 
GPR55 residues, while helices chosen from the CM output that would fit in the bundle 
were substituted in the bundle. This included a straightened TMH6 conformer for which 
the TMH3-TMH6 ionic lock was broken, reflecting the R* state. Incorporated into this 
new bundle were updates from previous homology models of GPR5513-14 created in this 
lab: The high degree of sequence homology between GPR55 and the CXCR4 receptor,11 
particularly in the EC regions, dictated several modifications to the model. These were 
(1) the introduction of                                                                                                                                    
EC helical extensions on TMH5-7 of GPR55; (2) the introduction of a β sheet motif  into 
the EC-2 loop in GPR55; and, (3) the introduction of a disulfide bridge between Cys(10) 
in the N-terminus and Cys(260) in the EC-3 loop near the top of TMH7. 
The resulting homology model was then optimized using the following protocol13: 
The energy of the GPR55 R* bundle was minimized using the OPLS 2005 force field in 
Macro-model 9.9 (Schrödinger Inc., Portland, OR). An 8.0-Å extended non-bonded 
cutoff (updated every 10 steps), a 20.0-Å electrostatic cutoff, and a 4.0-Å hydrogen bond 
cutoff were used in each stage of the calculation. The minimization was performed in 
three stages. Each stage consisted of a Polak- Ribier conjugate gradient minimization in 
1000-step increments until the bundle reached a 0.05 kJ/mol gradient. In the first stage of 
the calculation, the TMH region of the receptor was held stationary and the loops were 
allowed to relax using the generalized born/surface area continuum solvation model for 
water (Macro-model). In the second stage, the loops were frozen and the side chains of 
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the TMHs were allowed to adjust. A distance dependent dielectric was used for this 
minimization. In the third stage, the N and C termini were minimized using the protocol 
described, for the loops, above. In this stage, only the termini were minimized.  
Conformational Analysis of ML184 
A complete conformational analysis of the GPR55 agonist ML184 (CID2440433) 
was performed using ab initio Hartree-Fock (HF) calculations at the 6–31G* level as 
encoded in Jaguar (version 9.0, Schrodinger, LLC, New York, NY). Hartree-Fock 6–
31G* six-fold conformer searches were performed for the rotatable bonds, N1-S2, S2-C3, 
C4’-N5’, C4-C5, C5-N6, N7-C8 (see numbering system in Fig 29), of ML184 as follows: 
In each conformer search, local energy minima were identified by rotation of a subject 
torsion angle through 360° in 60° increments (6-fold search), followed by HF 6–31G* 
energy minimization of each rotamer generated. To calculate the energy difference 
between the global minimum energy conformer of ML184 and its final docked 
conformation, rotatable bonds in the global minimum energy conformer were driven to 
their corresponding value in the final docked conformation and the single point energy of 
the resultant structure was calculated at the HF 6–31G* level. This difference was 
calculated to be 1.91 kcal/mol. 
Docking of ML184 
A low free-energy conformer of ML184 was used as input for receptor docking. 
ML184 was initially docked manually in the binding site of the GPR55 R* model, after 
which the automatic docking program, Glide (Schrodinger Inc.), was used to explore 
other possible binding conformations and receptor site interactions. Extra precision (XP) 
92 
 
and flexible docking with ring sampling were selected for the docking setup. Lysine 
2.60(80), a previously identified ligand interaction site,12 was defined as a hydrogen bond 
donor and was used as a constraint for the automatic docking of the ligand. The energy of 
the ligand/GPR55 R* complex was minimized using the OPLS 2005 force field in 
Macro-model 9.9 (Schrödinger Inc., Portland, OR). An 8.0-Å extended non-bonded 
cutoff (updated every 10 steps), a 20.0-Å electrostatic cutoff, and a 4.0-Å hydrogen bond 
cutoff were used in each stage of the calculation as described previously. The dock with 
the best Glide score (-9.1) was selected as the final ML184/GPR55 R* model.  
Assessment of Pair-wise Interaction Energies 
After defining the atoms of ML184 as one group (Group 1) and the atoms 
corresponding to a residue that lines the binding site in the final ligand/GPR55 R* 
complex as another group (Group 2), Macromodel (version 8.6, Schrödinger, LLC, New 
York, NY) was used to output the pair-wise interaction energy (coulombic and Van der 
Waals) for a given pair of atoms. The pairs corresponding to Group 1 (ligand) and Group 
2 (residue of interest) were then summed to yield the interaction energy between the 
ligand and that residue. The ML184/GPR55 R* complex was found to have interaction 
energies totaling to -55.9 kcal/mol. Taking the conformational energy cost for ML184 
(1.91 kcal/mol) into account, the final total energy for the ML184/GPR55 R* complex 
was found to be -54.0 kcal/mol. A breakdown of interaction energies is provided in Table 
S-1. 
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CHAPTER V 
 
FUTURE CONSIDERATIONS 
 
Now that there are models of the GPR55 active and inactive states it is imperative 
that the models continue to be refined. It is also necessary that they be used as the tools 
that they were designed to be to suggest new directions for ligand development. 
Chemo-informatics Approach 
A shift in focus to other scaffolds will likely be needed owing to the fact that the 
analogs synthesized thus far have not reached low nanomolar efficacies. One approach to 
scaffold diversification is receptor-based core hopping. New scaffolds for both GPR55 
agonists and antagonists can be explored using the Schrodinger suite module 
CoreHopper. This task option in the Schrodinger small-molecule discovery suite allows 
for rapid screening of novel cores to help overcome undesirable properties of a ligand by 
creating new lead compounds with improved core properties while preserving key R-
group interactions. Core hopping can also potentially be used for generation of novel 
derivatives to a known ligand (such as LPI). Chemotypes produced by the CoreHopper 
program can be used to explore the 102 million-compound library of commercially 
available compounds in the IReasearch library in ChemNavigator. Once a subset of 
structures has been identified, these structures can then be converted to three-dimensional 
form, energy minimized and then subjected to high throughput docking in the updated 
models using the Induced Fit Docking module discussed in Chapter III.  
99 
 
Validating Chemo-informatics Virtual Search Results 
It would be necessary for select compounds from the virtual search to be 
purchased and evaluated in Dr. Abood’s lab. Antagonist compounds (initially at 10 M) 
could be screened for their ability to inhibit the β-arrestin trafficking caused by the 
GPR55 agonist, LPI, using high content imaging by established methodology (described 
in Chapter II. Compounds found to inhibit LPI’s β-arrestin trafficking can then be 1) 
counter-screened for their ability to inhibit receptor internalization and 2) their ability to 
antagonize LPI induced ERK1/2 signaling in a 96-well plate format using a LI-COR 
Odyssey imager for quantification of responses. Agonist compounds (initially at 10 M) 
will be screened for their ability to stimulate β-arrestin trafficking, using high content 
imaging as described in Chapter II. Compounds found to produce β-arrestin trafficking 
will be counter-screened for their ability to produce receptor internalization as described 
above.  
This would be the point in this endeavor where heretofore unassessed analogs 
could be designed using each new scaffold identified. If a large number of compounds is 
generated and found to be active, factors such as cost and future synthetic practicality 
will be used to filter the final range of compounds to be assessed. 
Unutilized Synthesis of Analogues for Scaffold 2 
The structure of Scaffold 2 (from the original Burnham Screen mentioned in 
Chapters I–IV previously) can be divided into two primary areas, the furyl amide and a 
tricyclic heteroaromatic group, either of which could be modified (Figure 41). The 
proposed synthetic plans are shown in Scheme 3 (Figure 42). The amide section of 18 can 
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be connected using the corresponding acid chloride,1 and there are a multitude of variants 
possible at this position. The fused, heteroaromatic section can be put together from 
readily available ketones, ethyl cyanoacetate, and elemental sulfur (S8) using the Gewald 
synthesis.2 The resulting 2-aminothiophene can be reacted with a nitrile under acidic 
conditions and then dehydrated using phosphoryl chloride to provide electrophilic 
coupling partners 20.3 These two sections can then  be brought together to provide the 
desired analogues (21).4 This synthesis can be modified as needed to give rise to the 
different compounds, but the basic route can be followed for most of the structures 
proposed in Figure 43.   
 
Figure 41. Scaffold 2. 
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Figure 42. Scheme 3: Synthetic Scheme for Scaffold 2. 
 
Figure 43. Analogs Proposed for Scaffold 2 Development. 
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The analogs that should be targeted for synthesis initially are ones that would 
modify the furan group due to the fact that there are very few commercially available 
structures that extend out in this area of the binding pocket. This area of the binding 
pocket is of known importance due to mutation data highlighting ligand interactions with 
K2.60 and Y3.32. Compounds 25 and 26 were designed to have an intramolecular 
hydrogen-bond to rigidify the structure in the binding pocket and to allow other moieties 
on the ligand to explore available space. Alcohol 27 explores the potential for additional 
hydrogen bonds (hydrogen bond donation to S7.32 and hydrogen bond acceptance with 
Q6.58).  
It is now known from the mutation data detailed in Chapter IV that Q6.58 does 
not interact with GPR55 agonists in the binding pocket as it sits high in the EC side of the 
receptor. It remains to be seen if that mutation would have an effect on antagonists of 
GPR55. Analogs in Figure 43 were proposed based on the fit they had with the original 
receptor model and so will need to be re-evaluated to confirm their validity in the current, 
model.  
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Graphical Abstract 
 
 
General Information 
Solvents and reagents were obtained from commercial sources and used without 
further purification; anhydrous solvents were dried following standard procedure, 
reaction progress was monitored by TLC (Silica gel 60 F254) glass plates visualized with 
UV light and permanganate stain. The anhydrous reactions were performed in oven dried 
glassware under nitrogen atmosphere. Chromatographic purification was performed using 
silica gel (60 Å, 32-63um). NMR spectra were recorded in CDCl3 using a Bruker 
AVANCE DRX 300 spectrometer (300 MHz for 1H), JEOL ECA spectrometer (500 
MHz for 1H and 125 MHz for 13C). Chemical shifts reported in ppm using 
tetramethylsilane as reference for the 1H NMR and the residual solvent peak for 13C (77 
ppm). The abbreviations used to describe peak splitting patterns are: s = singlet, d = 
doublet, t = triplet, sept = septet, dd = doublet of doublets, m = multiplet. Coupling 
constants, J, are reported in hertz (Hz). IR was obtained with Perkin Elmer FTIR 
Spectrometer One and Spectrometer 65 with ATR sampling accessories. Frequencies are 
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in cm-1. High Resolution Mass Spectra were acquired on a ThermoFisher Scientific LTQ 
Orbitrap XL MS system. 
Synthesis of Hydrazides 3a-f 
 
  The hydrazides 3v-x were synthesized following the reported procedure in the 
literaturei and hydrazides 3t, 3u, 3y, and 3z were purchased from Acros. Compound 3v 
matched the data previously reports and 3w and 3x, are fully characterized below. 
Characterization of Hydrazides 3w and 3x 
 
 
4-Trifluoromethyl-benzoic acid hydrazide (3w):  
White solid (2.54 g, 12.4 mmol, 75%).  
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1H NMR (CDCl3, 400 MHz): δ = 10.01 (s, 1H), 8.01 (d, J = 8.2 Hz, 2H), 7.81 (d, J = 8.2 
Hz, 2H), 4.59 (s, 2H).  
13C NMR (CDCl3, 100 MHz): δ = 164.6, 137.1, 131.2 (q, J = 31.5 Hz, 1C), 127.9 (2C), 
125.3 (q, J = 3.8 Hz, 2C), 123.9(q, J = 270.0 Hz, 1C).  
IR: 3335, 1621, 1577, 1536, 1504, 1318, 1136, 1112, 1065, 928, 865, 771, 690, 607 cm-1. 
HRMS (ESI): C8H8F3N2O+ [M+H]+ calculated: 205.05832; found: 205.05817. 
 
3-Trifluoromethyl-benzoic acid hydrazide (3x):  
White solid (85 mg, 0.42 mmol, 60%).  
1H NMR (CDCl3, 400 MHz): δ = 10.1 (s, 1H), 8.16 (s, 1H), 8.12 (d, J = 7.8 Hz, 1H), 7.85 
(d, J = 7.8 Hz, 1H), 7.69 (t, J = 7.8 Hz, 1H), 4.95 (s, 2H).  
13C NMR (CDCl3, 100 MHz): δ = 164.5, 134.3, 131.1, 127.8, 129.3 (q, J = 31.5 Hz, 1C), 
127.8 (q, J = 3.8 Hz, 1C), 124.1 (q, J = 270.8 Hz, 1C), 123.7 (q, J = 3.8 Hz, 1C).  
IR:  3305, 1639, 1615, 1518, 1482, 1437, 1321, 1308, 1283, 1161, 1119, 1090, 1070, 818, 
691, 642, 594 cm-1. 
HRMS (ESI): C8H8F3N2O+ [M+H]+ calculated: 205.05832; found: 205.05809. 
General Method for Synthesis of Piperidones 2a-f 
Thionyl chloride (4 eq) was added dropwise to an oven-dried round bottomed 
flask containing commercially available acid 1a-f (0.212 mmol – 29.0 mmol) and 
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dichloromethane (0.3 M). The reaction was stirred at 50 °C for one hour. The resulting 
solution was concentrated under vacuum and re-dissolved in dichloromethane (20 mL, 
0.11 M) and added dropwise to a round bottom flask at 0 °C containing 4-piperidone 
(1.26 eq), triethylamine (7.5 eq), and THF (0.06 M). After 15 minutes the solution was 
refluxed at 50 °C for 24 hours. The reaction was carefully quenched with saturated 
aqueous ammonium chloride and extracted with chloroform (3 x 20 mL). The resultant 
organic layers were combined and dried over Na2SO4, decanted and concentrated under 
vacuum. Product purification was achieved by silica gel flash chromatography (40% 
ethyl acetate/60% hexane). 
Characterization of Piperidones 2a-f 
 
1-(1-Phenyl-cyclopropanecarbonyl)-piperidin-4-one (2a):  
White solid (798 mg, 3.3 mmol, 36%). 
1H NMR (CDCl3, 400 MHz): δ = 7.35 - 7.26 (m, 2H), 7.25 - 7.21 (m, 3 H), 3.95- 3.67 (br, 
4H), 2.50 - 2.25 (br, 2H), 2.05 – 1.91 (br, 2H), 1.46 (dd, J = 6.9, 4.6 Hz, 2H), 1.24 (dd, J = 
6.9, 4.6 Hz, 2H).  
13C NMR (CDCl3, 100 MHz): δ = 207.4, 171.5, 140.3, 129.2 (2C), 127.0, 125.7 (2C), 44.5, 
41.9, 40.8 (2C), 29.8, 14.8 (2C).  
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IR: 3008, 2873, 2359, 2341, 1714, 1633, 1427, 1316, 1270, 1232, 1188, 1079, 981, 760, 
738, 698, 600, 572 cm-1. 
HRMS (ESI): C15H18NO3 [M-H+H2O] calculated: 260.12867; found: 260.1285. 
 
1-[1-(4-Methoxy-phenyl)-cyclopropanecarbonyl]-piperidin-4-one (2b):  
Pale yellow crystalline solid (2.51 g, 13.0 mmol, 52%).  
1H NMR (CDCl3, 500 MHz): δ = 7.16 (dt, J = 5.2, 2.9 Hz, 2H), 6.84 (dt, J = 5.7, 2.3 Hz, 
2H), 3.80 - 3.89 (m, 2H), 3.70 - 3.80 (br m, 2H), 3.78 (s, 3H) 2.39 (br m, 2H), 1.97 (br m, 
2H), 1.39 (dd, J = 6.9, 4.6 Hz, 2H), 1.16 (dd, J = 6.9, 4.6 Hz, 2H). 
13C NMR (CDCl3, 125 MHz): δ = 207.5, 171.8, 158.6, 132.2, 127.2 (2C), 114.5 (2C), 55.5, 
41.8 (2C), 40.7 (2C), 29.1, 14.3 (2C).  
IR: 2957, 1716, 1633, 1509, 1468, 1435, 1425, 1312, 1277, 1239, 1180, 1031, 979, 831, 
811, 652, 560 cm-1.  
HRMS (ESI): C16H20NO3 [M+H]+ calculated: 274.14377; found: 274.14304. 
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1-[1-(2,4,-Dichloro-phenyl)-cyclopropanecarbonyl]-piperidin-4-one (2c): 
White solid (540 mg, 1.73 mmol, 68%).  
1H NMR (CDCl3, 500 MHz): δ = 7.40 (s, 1H), 7.20 - 7.27 (m, 2H), 3.68 (br m, 4H), 2.15 
(br m, 4H), 1.67 (dd, J = 6.9, 4.6 Hz, 2H), 1.14 (dd, J = 6.9, 4.6 Hz, 2H).  
13C NMR (CDCl3, 125 MHz): δ = 207.1, 171.0, 137.8, 137.5, 133.8, 130.3, 130.0, 127.7, 
43.8 (2C), 40.8 (2C), 28.9, 14.6 (2C).  
HRMS (ESI): C15H15Cl2NO2 [M+H]+ calculated: 312.05581; found: 312.05524. 
 
1-[1-(4-Chloro-phenyl)-cyclopropanecarbonyl]-piperidin-4-one (2d):  
Pale yellow solid (5.06 g, 25.4 mmol, 21%).  
1H NMR (CDCl3, 500 MHz): δ = 7.29 (d, J = 8.6 Hz, 2H), 7.18 (d, J = 8.6 Hz, 2H), 3.90-
3.65 (br m, 4H), 2.41 (br m, 2H), 2.08 (br m, 2H), 1.47 (dd, J = 6.9, 4.6 Hz, 2H), 1.21 (dd, 
J = 6.9, 4.6 Hz, 2H).  
13C NMR (CDCl3, 125 MHz): δ = 207.0, 171.1, 138.9, 132.8, 129.4 (2C), 127.2 (2C), 44.5, 
41.9, 40.8 (2C), 29.4, 15.0 (2C).  
IR: 3009, 1726, 1685, 1491, 1388, 1371, 1338, 1247, 1178, 1096, 1045, 1014, 951, 931, 
828, 762, 753, 716, 678, 544 cm-1.  
HRMS (ESI): C15H17ClNO2 [M+H]+ calculated: 278.09423; found: 278.09387. 
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1-(2,2-Dimethyl-1-p-tolyl-cyclopropanecarbonyl)-piperidin-4-one (2e): 
White solid (160 mg, 0.560 mmol, 38%).  
1H NMR (CDCl3, 500 MHz): δ = 7.32 (d, J = 9.2 Hz, 2H), 7.10 (d, J = 9.2 Hz, 2H), 4.12-
3.98 (br m, 2H), 3.82-3.77 (br m, 1H), 3.55-3.49 (br m, 1H), 2.35-2.27 (br, 5H), 2.15-2.09 
(br m, 1H), 1.88-1.79 (br m, 1H), 1.31 (d, J = 5.2 Hz, 2H), 1.29 (s, 3H), 1.10 (d, J = 5.2 
Hz, 2H), 0.86 (s, 3H).  
13C NMR (CDCl3, 125 MHz): δ = 207.6, 170.9, 136.8, 134.7, 129.4 (2C), 129.1 (2C), 44.7, 
41.6, 41.2, 40.8, 38.5, 25.0 (2C), 24.5, 22.7, 21.2.  
IR: 2981, 2929, 2357, 2341, 1714, 1634, 1449, 1418, 1307, 1263, 1231, 1219, 1135, 1081, 
807, 760, 739, 657, 573 cm-1.  
HRMS (ESI): C18H23NO2 [M+Na]+ calculated: 308.1621; found:308.1639. 
 
1-(1-Naphthalen-2-yl-cyclopropanecarbonyl)-piperidin-4-one (2f):  
Clear oil oil (5.00 g, 29.0 mmol, 20%).  
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1H NMR (CDCl3, 500 MHz): δ = 7.94 - 7.89 (m, 2H), 7.88 – 7.85 (m, 1H), 7.57 - 7.77 (m, 
4H), 4.21 (t, J = 6.3 Hz, 2H), 3.51 (t, J = 6.0 Hz, 2H), 2.69 (t, J = 6.3 Hz, 2H), 2.32 (q, J = 
6.3 Hz, 2H).  
13C NMR (CDCl3, 100 MHz): δ = 206.5, 169.6, 133.4, 133.3, 129.4, 129.3, 128.5, 127.2, 
126.5, 125.1, 124.3, 123.6, 45.7, 41.5, 40.9, 40.8.  
IR: 3053, 2964, 2360, 1713, 1631, 1507, 1470, 1435, 1366, 1314, 1279, 1244, 1199, 1150, 
973, 800, 780, 627 cm-1.  
HRMS (ESI): C16H16NO2+ [M+H]+ calculated: 254.11756; found: 254.11882. 
General Method for Synthesis of Oxadiazolones 5 
Ketones 2a-f (0.083 mmol – 5.40 mmol) was combined with the corresponding hydrazine 
(3t-z; 1.09 eq) and methanol (0.05 M) in an oven-dried round bottomed flask and stirred 
at 30 °C for 1 hour. The temperature was raised to 50 °C for an additional 2 hours. The 
reaction was cooled to 0 °C and sodium borohydride (1.05 eq) was added. The reaction 
was allowed to warm to room temperature, stirred for 2 hours, quenched with brine, and 
extracted with dichloromethane (3 x 20 mL). The resultant organic layer was dried over 
Na2SO4, decanted, and concentrated under vacuum. The crude hydrazide (4) was then 
solubilized in THF (0.011 M) at 0 °C and triethylamine (2.6 eq) and triphosgene (0.67 
eq) were sequentially added. The reaction was stirred at room temperature for 24 hours, 
quenched with brine, and extracted with ethyl acetate (3 x 20 mL). The resultant organic 
layer was dried over Na2SO4, decanted and concentrated under vacuum. Product 
purification was achieved by silica gel flash chromatography (gradient elution starting 
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with 25:75 ethyl acetate:hexane and ending with a 50:50 ethyl acetate:hexane) to yield 
azoxazolones 5.  
Characterization of Oxadiazolones 5 
 
5-Phenyl-3-[1-(1-phenyl-cyclopropanecarbonyl)-piperidin-4-yl]-3H-[1,3,4]oxadiazol-
2-one (5at): 
White solid (100 mg, 0.257 mmol, 74%). 
1H NMR (CDCl3, 500 MHz): ẟ = 7.83-7.80 (m, 2H), 7.54 - 7.42 (m, 3H), 7.36 - 7.31 (m, 
2H), 7.25-7.18 (m, 3H), 4.76-4.75 (br m, 1H), 4.28-4.10 (br m, 2H), 2.97-2.75 (br m, 2H), 
2.01-1.90 (br m, 2H), 1.75-1.66 (br m, 1H), 1.65-1.52 (br, 1H), 1.50-1.41 (br m, 2H), 1.25-
1.18 (br m, 2H).  
13C NMR (CDCl3, 100 MHz): δ = 171.1, 153.5, 153.0, 140.6, 131.8, 129.1 (2C), 129.0 
(2C), 126.6, 125.8 (2C), 125. 5 (2C), 123.9, 53.2, 44.6, 41.3, 29.8 (2C), 29.6, 15.3 (2C).  
IR: 2934, 2359, 2341, 1772, 1635, 1449, 1431, 1353, 1154, 993, 739, 690, 580 cm-1.  
HRMS (ESI): C46H47N6O6 [2M+H]+ calculated: 779.35516; found: 779.3574. 
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3-[1-(1-phenyl-cyclopropanecarbonyl)-piperidin-4-yl]-5-pyridin-3-yl-3H-
[1,3,4]oxadiazol-2-one (5au):  
Light yellow-orange solid (105 mg, 0.269 mmol, 13%). 
1H NMR (CDCl3, 500 MHz): ẟ = 9.06 (br s, 1H), 8.74 (br s, 1H), 8.06 (dt, J = 2.0, 8.0 Hz, 
1H), 7.42 (dd, J = 5.1, 8.0 Hz, 1H), 7.33 - 7.31 (m, 2H), 7.23-7.18 (m, 3H), 4.77-4.72 (br 
m, 1H), 4.28-4.10 (br m, 2H), 2.95-2.72 (br m, 2H), 2.01-1.88 (br m, 2H), 1.75-1.66 (br, 
1H), 1.65-1.60 (br, 1H), 1.49-1.40 (br m, 2H), 1.25-1.18 (br m, 2H).  
13C NMR (CDCl3, 100 MHz): δ = 171.1, 152.6, 152.4, 151.5, 147.1, 140.6, 133.0, 129.0 
(2C), 126.7, 125.5 (2C), 123.9, 120.5, 53.5, 44.6, 41.3, 29.8 (2C), 29.6, 15.3 (2C).  
IR: 3179, 2955, 2863, 1784, 1625, 1610, 1456, 1432, 1412, 1328, 1160, 988, 740,702, 690, 
580 cm-1.  
HRMS (ESI): C46H47N6O6 [2M+H]+ calculated: 779.35516; found: 779.3574. 
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5-(4-Methoxy-phenyl)-3-[1-(1-phenyl-cyclopropanecarbonyl)-piperidin-4-yl]-3H-
[1,3,4]oxadiazol-2-one (5av):  
White solid (223 mg, 0.53 mmol 43%). 
1H NMR (CDCl3, 400 MHz): ẟ = 7.76 (d, J = 9.0, 2H), 7.37-7.29 (m, 2H), 7.25 -7.17 (m, 
3H), 6.96 (d, J = 9.0 Hz, 2H), 4.74 (br s, 1H), 4.32-4.17 (br s, 1H), 4.12 (sept, J = 5.0 Hz, 
1H), 3.87 (s, 3H), 2.98-2.70 (br m, 2H), 2.05-1.84 (br m, 2H), 1.80-1.65 (br m, 1H), 1.64-
1.50 (br, 1H), 1.51-1.35 (br, 2H), 1.30-1.14 (br, 2H).  
13C NMR (CDCl3, 100 MHz): δ = 171.2, 162.4, 153.6, 153.2, 140.7, 129.0 (2C), 127.6 
(2C), 126.6, 125.5 (2H), 116.4, 114.6 (2C), 55.7, 53.1, 44.6, 41.3, 29.9 (2C), 29.6, 15.3 
(2C).  
IR: 2936, 1765, 1632, 1612, 1508, 1440, 1352, 1249, 1176, 1161, 1029, 1017, 836, 744, 
693, 609, 574 cm-1.  
HRMS (ESI): C24H26N3O4 [M+H]+ calculated: 420.19178, found: 420.18976. 
 
3-[1-(1-phenyl-cyclopropanecarbonyl)-piperidin-4-yl]-5-(4-trifluoromethyl-phenyl)-
3H-[1,3,4] oxadiazol-2-one (5aw):  
White solid (85.1 mg, mmol 87%).  
1H NMR (CDCl3, 400 MHz): ẟ = 7.94 (d, J = 8.1 Hz, 2H), 7.75 (d, J = 8.1 Hz, 2H), 7.37-
7.32 (m, 2H), 7.25 -7.17 (m, 3H), 4.77 (br, 1H), 4.30-4.13 (br m, 2H), 2.97-2.73 (br m, 
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2H), 2.05-1.83 (br m, 2H), 1.80-1.65 (br m, 1H), 1.64-1.50 (br, 1H), 1.50-1.35 (br, 2H), 
1.32-1.18 (br, 2H).  
13C NMR (CDCl3, 100 MHz): δ = 171.2, 152.7, 152.3, 140.6, 133.3 (q, J = 32.4 Hz, 1C), 
129.0 (2C), 127.2, 126.7, 126.2 (q, J = 3.8 Hz, 2C), 126.1 (2C), 125.5 (2C), 123.7 (q, J = 
271.0 Hz, 1C), 53.5, 44.6, 41.3, 29.9 (2C), 29.6, 15.2 (2C).  
IR: 2846, 2863, 2354, 2341, 1776, 1633, 1437, 1321, 1170, 1150, 1119, 1107, 1063, 1011, 
992, 856, 847, 736, 699, 570, 515 cm-1.  
HRMS (ESI): C24H22F3N3NaO3 [M+Na]+ calculated: 480.15054 found: 480.1529 
 
3-[1-(1-phenyl-cyclopropanecarbonyl)-piperidin-4-yl]-5-(3-trifluoromethyl-phenyl)-
3H-[1,3,4] oxadiazol-2-one (5ax):  
White solid (117 mg, 0.253 mmol, 62%).  
1H NMR (CDCl3, 500 MHz): ẟ = 8.09 (s, 1H), 8.00 (d, J = 7.8 Hz, 1H), 7.75 (d, J = 7.8 
Hz, 1H), 7.63 (t, J = 7.8 Hz, 1H), 7.34 (t, J = 7.8 Hz, 2H), 7.25 -7.20 (m, 3H), 4.77 (br, 
1H), 4.30-4.13 (br m, 2H), 3.00 - 2.80 (br m, 2H), 2.05-1.83 (br m, 2H), 1.80-1.65 (br m, 
1H), 1.64-1.50 (br, 1H), 1.50-1.35 (br, 2H), 1.32-1.18 (br, 2H).  
13C NMR (CDCl3, 100 MHz): δ = 171.8, 152.7, 152.3, 140.6, 132.0 (q, J = 33.4 Hz, 1C), 
129.9, 129.0 (2C), 128.8, 128.2 (q, J = 3.8 Hz, 1C), 126.7, 125.6 (2C), 124.8, 123.6 (q, J = 
271.0 Hz, 1C), 122.7 (q, J = 3.8 Hz, 1C), 53.5, 44.6, 41.3, 29.9 (2C), 29.6, 15.2 (2C).  
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IR: 2934, 2360, 2340, 1778, 1736, 1638, 1431, 1307, 1276, 1169, 1155, 1128, 1073, 1032, 
994, 743, 693, 575 cm-1.  
HRMS (ESI): C24H23F3N3O3+ [M+H]+ calculated: 458.16860, found: 458.16885. 
  
5-Furan-2-yl-3-[1-(1-phenyl-cyclopropanecarbonyl)-piperidin-4-yl]-3H-
[1,3,4]oxadiazol-2-one (5ay):  
White solid (79 mg, 0.208 mmol, 51%).  
1H NMR (CDCl3, 500 MHz): ẟ = 7.59 (d, J = 1.8 Hz, 1H), 7.34-7.31 (m, 2H), 7.23-7.17 
(m, 3H), 6.97 (d, J = 3.7 Hz, 1H), 6.56 (dd, J = 3.7, 1.8 Hz, 1H), 4.72 (br, 1H), 4.29-4.10 
(br m, 2H), 2.95-2.70 (br m, 2H), 2.05-1.90 (br m, 2H), 1.80-1.57 (br m, 2H), 1.45 (br, 
2H), 1.21 (br, 2H).  
13C NMR (CDCl3, 125 MHz): δ = 171.1, 152.1, 149.9, 145.8, 140.6, 139.0, 129.0 (2C), 
126.6, 125.3 (2C), 113.9, 112.2, 53.5, 44.6, 42.2, 29.8 (2C), 29.5, 15.3 (2C).  
IR: 2928, 2861, 2359, 2341, 1778, 1634, 1434, 1326, 1151, 1038, 995, 949, 904, 741, 699, 
572 cm-1.  
HRMS (ESI): C42H43N6O8 [2M+H]+ calculated: 759.31369 found: 759.3155. 
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3-[1-(1-Phenyl-cyclopropanecarbonyl)-piperidin-4-yl]-5-thiophene-2-yl-3H-
[1,3,4]0xadiazol-2-one (5az):  
White solid (80 mg, 0.202 mmol, 49%).  
1H NMR (CDCl3, 500 MHz): ẟ = 7.56 (dd, J = 1.3, 3.8 Hz, 1H), 7.50 (dd, J = 1.3, 5.0 Hz, 
1H), 7.35-7.31 (m, 2H), 7.24-7.18 (m, 3H), 7.12 (dd, J = 3.8, 5.0 Hz, 1H), 4.80-4.65 (br, 
1H), 4.25-4.15 (br, 1H), 4.15-4.05 (m, 1H), 2.95-2.70 (br m, 2H), 2.00-1.85 (br, 2H), 1.75-
1.62 (br, 1H), 1.62-1.50 (br, 1H), 1.45 (br, 2H), 1.22 (br, 2H).  
13C NMR (CDCl3, 100 MHz): δ 171.0, 152.2, 150.0, 140.3, 129.7, 129.2, 128.8 (2C), 
128.0, 126.5, 125.3, 125.2 (2C), 53.1, 44.4, 41.1, 29.6 (2C), 29.4, 15.1 (2C).  
IR: 3085, 2928, 2860, 2358, 2341, 1768, 1633, 1613, 1430, 1324, 1272, 1153, 1045, 1012, 
987, 857, 738, 699, 578 cm-1.  
HRMS (ESI): C21H22N3O3S[M+H]+ calculated: 396.13764; found: 396.1381. 
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3-{1-[1-(4-Methoxy-phenyl)-cyclopropanecarbonyl]-piperidin-4-yl}-5-phenyl-3H-
[1,3,4]oxadiazol-2-one (5bt):  
White solid (190 mg, 0.453 mmol 62%).  
1H NMR (CDCl3, 500 MHz): ẟ = 7.81 (br d, J = 6.7 Hz, 2H), 7.51-7.45 (m, 3H), 7.15 (br 
d, J = 9.0 Hz, 2H), 6.86 (br d, J = 9.0 Hz, 2H), 4.80-4.65 (br, 1H), 4.35-4.20 (br m, 1H), 
4.14 (tt, J = 4.6, 10.9 Hz, 1H), 3.78 (s, 3H), 3.00-2.70 (br m, 2H), 2.08-1.51 (br m, 4H), 
1.47-1.35 (br m, 2H), 1.20-1.12 (br m, 2H).  
13C NMR (CDCl3, 100 MHz): δ 171.4, 158.3, 153.5, 153.1, 132.6, 131.8, 129.1, 126.8, 
125.8 (4C), 123.9, 114.4, 114.3, 55.5, 53.3, 53.1, 44.5, 41.3, 29.9, 29.1, 14.7 (2C).  
IR: 2906, 2869, 1763, 1629, 1513, 1449, 1430, 1322, 1245, 1181, 1154, 1038, 1021, 997, 
856, 823, 731, 684, 657, 592, 572 cm-1.  
HRMS (ESI): C24H26N3O4 [M+H]+ calculated: 420.19178; found: 420.1928. 
 
5-(4-Methoxy-phenyl)-3-{1-[1-(4-methoxy-phenyl)-cyclopropanecarbonyl]-
piperidin-4-yl}-3H-[1,3,4]oxadiazol-2-one (5bv):  
White solid (91.4 mg, 0.209 mmol 81%).  
1H NMR (CDCl3, 500 MHz): ẟ = 7.75 (br d, J = 9.2 Hz, 2H), 7.14 (br d, J = 9.2 Hz, 2H), 
6.96 (br d, J = 9.2 Hz, 2H), 6.87 (br d, J = 9.2 Hz, 2H), 4.80-4.65 (br, 1H), 4.35-4.18 (br, 
1H), 4.12 (tt, J = 10.9, 4.6 Hz, 1H), 3.87 (s, 3H), 3.79 (s, 3H), 3.00-2.70 (br m, 2H), 2.02-
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1.80 (br, 2H), 1.80-1.64 (br, 1H), 1.64-1.50 (br, 1H), 1.48-1.36 (br m, 2H), 1.20-1.12 (br 
m, 2H).  
13C NMR (CDCl3, 125 MHz): δ = 171.4, 162.4, 158.3, 153.6, 153.2, 132.6, 127.6 (2C), 
126.9 (2C), 116.4, 114.6 (2C), 114.3 (2C), 55.7, 55.5, 53.1, 44.6, 41.3, 29.9 (2C), 29.1, 
14.7 (2C).  
IR: 2948, 2357, 2341, 1762, 1632, 1509, 1436, 1246, 1176, 1156, 1025, 996, 832, 740, 
733, 607, 571, 525 cm-1.  
HRMS (ESI): C25H28N3O5 [M+H]+ calculated: 450.20235; found: 450.2014. 
 
3-{1-[1-(4-Methoxy-phenyl)-cyclopropanecarbonyl]-piperidin-4-yl}-5-(4-
trifluoromethyl-phenyl)-3H-[1,3,4]oxadiazol-2-one) (5bw):  
White solid (104 mg, 0.213 mmol, 88%).  
1H NMR (CDCl3, 500 MHz): ẟ = 7.94 (d, J = 8.1 Hz, 2H), 7.74 (d, J = 8.1 Hz, 2H), 7.15 
(br d, J = 8.6 Hz, 2H), 6.87 (br d, J = 8.6 Hz, 2H), 4.80-4.66 (br, 1H), 4.35-4.20 (br, 1H), 
4.16 (tt, J = 10.9, 4.0 Hz, 1H), 3.78 (s, 3H), 3.00-2.70 (br m, 2H), 2.05-1.85 (br, 2H), 1.80-
1.64 (br, 1H), 1.64-1.48 (br, 1H), 1.42-1.34 (br m, 2H), 1.21-1.10 (br m, 2H).  
13C NMR (CDCl3, 125 MHz): δ = 171.5, 158.4, 152.7, 152.3, 133.3 (q, J = 32.5 Hz, 1C), 
132.6, 127.2, 127.0 (2C), 126.2 (q, J = 3.8 Hz, 2C), 126.1 (2C), 123.7 (q, J = 272.5 Hz, 
1C), 114.4 (2C), 55.5, 53.5, 44.5, 41.3, 29.9 (2C), 29.1, 14.60 (2C).  
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IR: 2954, 2924, 2359, 2341, 1784, 1622, 1513, 1441, 1415, 1321, 1250, 1157, 1127, 1064, 
1029, 994, 854, 819, 748, 735, 590, 560 cm-1.  
HRMS (ESI): C25H25F3N3O4 [M+H]+ calculated: 488.17917; found: 488.1795. 
 
3-{1-[1-(2,4-Dichloro-phenyl)-cyclopropanecarbonyl]-piperidin-4-yl}-5-phenyl-3H-
[1,3,4]oxadiazol-2-one (5ct):  
White solid (35.9 mg, 0.078 mmol 48%).  
1H NMR (CDCl3, 300 MHz): ẟ = 7.82 (dd, J = 7.8, 1.5 Hz, 2H), 7.53-7.45 (m, 4H), 7.26-
7.23 (m, 2H), 4.49-4.18 (br m, 2H), 4.11 (tt, J = 10.9, 4.6 Hz, 1H), 2.81 (td, J = 11.5, 2.3 
Hz, 2H), 1.87-1.76 (br m, 2H), 1.74 – 1.59 (m, 4H), 1.18 - 1.12 (br m, 2H).  
13C NMR (CDCl3, 125 MHz): δ = 170.7, 153.5, 153.1, 138.0, 137.5, 133.5, 131.8, 130.4, 
130.1, 129.2 (2C), 127.5, 125.8 (2C), 123.9, 53.0, 43.7 (2C), 29.8 (2C), 28.9, 14.4 (2C).  
IR: 2924, 2852, 2358, 2341, 1815, 1770, 1717, 1615, 1449, 1350, 1275, 1066, 957, 920, 
772, 729, 688, 572 cm-1.  
HRMS (ESI): C23H22Cl2N3O3 [M+H]+ calculated: 458.10382; found: 458.10321. 
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3-{1-[1-(4-Chloro-phenyl)-cyclopropanecarbonyl]-piperidin-4-yl}-5-phenyl-3H-
[1,3,4]oxadiazol-2-one) (5dt):  
White solid (0.404 mg, 0.95 mmol, 19%).  
1H NMR (CDCl3, 500 MHz): ẟ = 7.84-7.80 (m 2H), 7.54-7.45 (m, 3H), 7.31 (br d, J = 8.6 
Hz, 2H), 7.14 (br d, J = 8.6 Hz, 2H), 4.85-4.70 (br, 1H), 4.20-4.11 (br, 1H), 4.15 (tt, J = 
10.9, 4.6 Hz, 1H), 3.00-2.70 (br m, 2H), 2.04-1.85 (br, 2H), 1.85-1.67 (br, 1H), 1.67-1.54 
(br, 1H), 1.54-1.40 (br m 2H), 1.25-1.15 (br m, 2H).  
13C NMR (CDCl3, 100 MHz): δ = 170.6, 153.5, 153.0, 139.3, 132.4, 132.0, 129.1 (3C), 
127.0, 125.8 (4C), 123.9, 53.1, 44.6, 41.4, 29.9 (2C), 29.2, 15.4 (2C).  
IR: 2939, 2864, 2359, 2341, 1765, 1636, 1613, 1492, 1430, 1401, 1356, 1324, 1154, 1097, 
1036, 1021, 1011, 992, 813, 738, 691, 583 cm-1.  
HRMS (ESI): C23H23ClN3O3 [M+H]+ calculated: 424.14225; found: 424.1425. 
 
3-[1-(2,2-Dimethyl-1-p-tolyl-cyclopropanecarbonyl)-piperidin-4-yl]-5-phenyl-3H-
[1,3,4]oxadiazol-2-one (5et):  
White solid (72 mg, 0.172 mmol, 49%).  
1H NMR (CDCl3, 500 MHz): δ = 7.83 (d, J = 7.0 Hz, 1H), 7.76 (d, J = 7.0 Hz, 1H), 7.53-
7.43 (br m, 3H), 7.34 (d, J = 8.1 Hz, 2H), 7.16-7.11 (br m, 2H), 4.68-4.43 (br m, 2H), 4.17-
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4.08 (br m, 1H), 3.21-2.90 (br m, 1H), 2.70-2.63 (br m, 1H), 2.32 (s, 3H), 1.95-1.70 (br m, 
4H), 1.32-1.22 (br, 4H), 1.12-1.06 (m, 1H), 0.87 (s, 3H).  
13C NMR (CDCl3, 125 MHz, multiple peaks observed due to rotational isomers): δ 170.7 
& 170.6 (1C, C12), 153.5 & 153.2 (1C, C8), 153.0 (1C, C7), 136.5 & 136.4 (1C, C17), 
135.1 (1C, C20), 131.7 & 131.6 (1C, C3), 129.4 (2C, C19, C21), 129.2 (2C, C2, C4), 129.1 
(2C, C1, C5), 125.7 & 125.6 (2C, C18, C22), 123.9 (1C, C6), 53.3 & 53.1 (1C, C9), 44.7 
& 44.4 (1C, C11), 40.9 & 40.8 (1C, C11’), 38.6 (1C, C13), 30.3 & 30.2 & 30.1 & 29.5 
(2C, C10, C10’), 25.2 (2C, C16, C14), 24.5 & 24.1 (1C, C15), 22.8 & 22.7 (1C, C16’), 
21.2 (1C, C23).  
IR: 2931, 2867, 1776, 1618, 1447, 1431, 1354, 1325, 1038, 1019, 992, 736, 686, 569, 518 
cm-1.  
HRMS (ESI): C27H31N3O5 [M+FA-H]- calculated: 476.21910; found: 476.2206. 
 
3-[1-(1-Naphthalen-1-carbonyl)-piperidin-4-yl]-5-phenyl-3H-[1,3,4]oxadiazol-2-one) 
(5ft):  
White solid (0.677 mg, 1.70 mmol, 60%). 
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1H NMR (CDCl3, 500 MHz): δ = 8.09 - 7.78 (m, 5H), 7.64 – 7.40 (m, 7H), 5.06 (d, J = 
13.0 Hz, 1H), 4.33 - 4.23 (m, 1H), 3.62 – 3.53 (m, 1H), 317 – 3.02 (m, 2H), 2.29 – 2.11 
(m, 2H), 2.01 – 1.74 (m, 2H).  
13C NMR (CDCl3, 100 MHz, multiple peaks observed due to rotational isomers): δ = 169.5, 
153.5, 152.9, 134.0, 133.5, 131.7, 129.7, 129.5, 129.3, 129.0 (2C), 128.6, 127.2, 126.6, 
125.7 (2C), 125.2, 124.8, 123.7, 53.1, 46.0, 40.5, 31.0, 30.1.  
IR: 2933, 2359, 2341, 1768, 1629, 1448, 1436, 1352, 1323, 981, 796, 777, 732, 687, 675, 
632, 584 cm-1.  
HRMS (ESI): C24H21N3NaO3 [M+Na]+ calculated: 422.14751; found: 422.1471. 
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Biological Assay 
Antagonist activity was evaluated based on the inhibition of LPI-induced β-
arrestin activity through the use of two differential means of β-arrestin quantitation, and 
in two different cellular backgrounds. Compounds were initially screened in an image 
based cell assay to identify their antagonist activity on their ability to inhibit LPI-induced 
β-arrestin recruitment. In this assay, U2OS cells over-expressing GPR55 (modified at the 
C-terminus, GPR55E) and GFP tagged β-arr2, are grown on glass coverslips and pre-
incubated (30 minutes) with candidate antagonists prior to LPI exposure (6μM; 40 
minutes). Images of cells were taken using a fluorescent microscope and analyzed with 
Image J (http://rsbweb.nih.gov/ij/) using a custom written plug-in. The modified GPR55E 
receptor, concentration of agonist (EC80), and details of the β-arrestin recruitment assay 
have been previously described.11,12 Compounds with an IC50 below 15μM were also 
evaluated employing DiscoveRx PathHunter® Complementation technology. CHO-K1 
cells stably expressing GPR55 (fused to a -galactosidase enzyme fragment), and -
arrestin (fused to an N-terminal deletion -galactosidase mutant), were grown in selection 
media and were passaged up to 10 times according to manufacturer protocols. In the 
presence of agonist (LPI, 90 minutes), and PathHunter® detection reagents containing β-
galactosidase substrate, a chemiluminescent signal is generated due to the forced 
complementation of the GPR55 fused β-galactosidase fragment and the β-arrestin fused 
N-terminal deletion mutant fragment of β-galactosidase. A concentration response curve 
was generated, and antagonist activity was evaluated based on the inhibition of the LPI-
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induced chemiluminescence signal. Prior to exposure with LPI (37 C, 90 minutes) cells 
were preincubated with putative antagonists for 30 minutes (37 C).  
The chemiluminesence signal was measured using a Perkin Elmer Envision plate 
reader for 1 second. Experiments were run in triplicate and repeated at a minimum of 3 
times. Ligand readings, expressed as relative luminescence units, were subtracted from 
corresponding vehicle readings and analyzed in GraphPad Prism version 5.0 (GraphPad, 
San Diego, CA). IC50 values of antagonists were similar in both β-arrestin methodologies, 
and in both cellular backgrounds. 
Modeling Methodsii 
Conformational Analysis of ML191 ((CID23612552), 5-phenyl-3-(1-(1-(p-
tolyl)cyclopropane-carbonyl)piperidin-4-yl)-1,3,4-oxa-diazol-2(3H)-one). A complete 
conformational analysis of ML191 was performed using ab initio Hartree-Fock 
calculations at the 6-31G* level as encoded in Spartan '08 (Wavefunction, Inc., 18401 
Von Karman Ave., Suite 370, Irvine, CA 92612). In each conformer search, local energy 
minima were identified by rotation of a subject torsion angle through 360° in 60° 
increments (6-fold search), followed by HF 6-31G* energy minimization of each rotamer 
generated. To calculate the energy difference between the global minimum energy 
conformer of ML191 and its final docked conformation, rotatable bonds in the global 
minimum energy conformer were driven to their corresponding value in the final docked 
conformation and the single point energy of the resultant structure was calculated at the 
HF 6-31G* level. 
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Electrostatic Potential Map Calculation - The electrostatic potential density 
surface for ML191 was calculated using Spartan '08 (Wavefunction, Inc., 18401 Von 
Karman Ave., Suite 370, Irvine, CA 92612). The electrostatic potential energy was 
calculated using the ab initio Hatree-Fock method at 6-31G* level of theory and was 
mapped on the 0.002 isodensity surface of each molecule. The surface was color coded 
according to the potential, with electron rich regions colored red and electron poor 
regions colored blue.  
Receptor Model Development - The construction of our initial GPR55 receptor 
homology model was described previously in Kotsikorou et al.iii This homology model 
used the crystal structure of β2-ARiv as the template.  This initial model has been 
modified to reflect several structural elements found in the x-ray crystal structure of 
CXCR4 in its inactive state, a receptor with which the GPR55 receptor has high 
homology.v  1) TMH2 and TMH4 of GPR55 were modeled using the corresponding 
helices in the CXCR4 structure. GPR55 and CXCR4 have prolines in the positions 2.58 
and 4.59 that would lead to very different conformations of TMHs 2 and 4 compared to 
the β2-AR template which has prolines at 2.59 and 4.60. In addition, preceding the 
prolines at positions 2.56 and 4.57, CXCR4 has threonines in a g- conformation that 
influence the overall bend of each helix. Analogously, GPR55 has serines at 2.56(76) and 
4.57(153) that can assume a g- conformation. Therefore, the use of the CXCR4 TMH2 
and TMH4 as templates is well-justified. 2) The high sequence homology between 
GPR55 and CXCR4 in the extracellular ends of TMHs 6 and 7, dictated the introduction 
of extracellular (EC) helical extensions to the EC3 loop of GPR55 to match that of 
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CXCR4. 3) The EC2 loop in CXCR4 contains a beta sheet. Due to high sequence 
similarity in this region, as well, the beta sheet motif was built into the EC-2 loop in 
GPR55. 4) In addition to the disulfide bridge between the EC-2 loop and C3.25, CXCR4 
has another disulfide bridge between a Cys in the N-terminus Cys(28)  and  Cys(274) in 
the EC-3 loop. The same residues (Cys(10) and Cys(260)) are found in the GPR55 
sequence, so this second disulfide bridge was added to the GPR55 model. Recent C(10)A 
and C(260)A mutation studies suggest that the C(10)/C(260) disulfide bridge exists in 
GPR55 (M. Lingerfelt et al., 2016, manuscript submitted). The GPR55 inactive state 
model is also characterized by an intracellular hydrogen bond between R3.50(119) and 
Q6.30(221) that closes off the intracellular domain of the receptor, preventing G-protein 
interaction. The resultant homology model was energy minimized to relieve any steric 
overlaps.  
Docking of Ligands - The lowest energy conformation of ML191 was used as 
input for receptor docking studies. The Schrödinger workflow, Induced Fit, (Schrödinger 
Inc. Portland, OR) was used to explore possible binding conformations and receptor site 
interactions in the GPR55 R model. The Induced Fit Docking workflow was used to dock 
subject ligands in the binding site of the GPR55 R receptor model. The binding site of the 
receptor was defined by the area enclosed in a box with dimensions 26Å x 26Å x26Å (the 
default value). Because the endogenous ligand, LPI, is negatively charged, it is very 
likely that a positively charged amino is the primary interaction site for GPR55 ligands. 
The only positively charged amino acid in the binding pocket is K2.60(80). Recent 
K2.60A mutation studies suggest that this residue is essential for ligand activation at 
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GPR55 (M. Lingerfelt et al., manuscript in preparation). For this reason, K2.60(80) was 
set as the center of the box and a hydrogen bond with K2.60(80) was defined as a 
constraint. The two constraints (enclosing box and hydrogen bond) were used for both 
docking steps that Induced Fit Docking performs. The initial receptor minimization that 
Induced Fit Docking performs in preparation for docking the ligand was omitted since the 
receptor model was already energy minimized. For the first Glide calculation, the 
receptor and ligand Van der Waals radii were set to the default value of 0.50 and the 
number of maximum poses to be produced was also set to 40. During the Prime stage of 
the calculation, amino acids within 5.0Å of the ligand were refined to better 
accommodate the ligand. Since the GPR55 receptor is a transmembrane protein, an 
implicit membrane was used during the Prime refinement step. Then, during the second 
Glide step, the top 30 poses produced by the first calculation were redocked to the 
receptor. Docked poses that were within 40.0 kcal/mol from the lowest one were kept.  
Ligand/Receptor Minimization - To optimize the ligand/receptor interaction in 
the receptor/ligand complexes, each was minimized using Macromodel 9.1 (Schrödinger 
Inc.; Portland, OR). Since the receptor model was minimized before the docking of the 
ligands, a brief minimization was adequate to resolve any steric clashes after docking. To 
this end, 500 steps of Polak-Ribier conjugate gradient minimization using force field 
defined dielectric were performed. A harmonic constraint was placed on all the TMH 
backbone torsions (φ, ψ, and ω) to preserve the general shape of the helices during 
minimization. The sidechains of the TMH region, the loops and termini were allowed to 
relax. The Generalized Born/Surface Area (GB/SA) continuum solvation model for water 
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as is implemented in Macromodel 9.1 was used for minimizing the loop regions. An 8.0Å 
nonbonded cutoff (updated every 10 steps), a 20.0Å electrostatic cutoff, and a 4.0Å 
hydrogen bond cutoff were used in each stage of the calculation. The transmembrane 
region and the docked ligand were frozen while the loops were minimized. 
Results 
ML191 Global Minimum Energy Conformer. Overall, the GPR55 probe 
molecules have three regions. The first two regions include a broad head connected to a 
central portion of the ligand that is vertical. Together, this gives ML191 the shape of the 
number “7”. The third section at the end of the vertical segment is a pendant aromatic or 
heterocyclic ring that is nearly perpendicular to the vertical segment.   In the global 
minimum energy conformer of ML191, the para-methylphenyl ring is at an angle with 
the carbonyl group that joins the cyclopropyl and the piperidine rings (C1-C2-C3-C4 = 
53.5° and C2-C3-C4-N6 = 72.5°). The piperidine, which is in a chair conformation, and 
the attached 1,3,4-oxadiazo-2-one ring form the vertical segment of the “7”. The 1,3,4-
oxadiazo-2-one ring is perpendicular to the plane of the piperidine ring (H-C9-N10-C11 
= -179.9°) and the pendant phenyl ring is in plane with the 1,3,4-oxadiazo-2-one ring 
(O12-C13-C14-C15 = -0.4°). The global minimum energy conformer of ML191 is 
illustrated in Figure 15B (bottom). 
ML191 Molecular Electrostatic Potential Map - Figure 15B (top) illustrates the 
molecular electrostatic potential map (ranges in kJ/mol given next to ligand) of the 
docked conformation of ML191 at GPR55 R. Below this map, the ML191 conformer 
used to calculate the map is shown in tube display (Figure 15B (bottom). ML191 
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possesses a broad head region connected to a central portion of the ligand that has a thin 
profile. The most electronegative region of ML191 is located close to the end of this 
central section and this portion is followed by a pendant ring that juts out nearly 
perpendicular to the central portion of the molecule. The carbonyl oxygen of the 1,3,4-
oxadiazo-2-one ring of ML191 is the most electronegative region of the ligand and forms 
the part of ML191 that interacts with K2.60(80) (see docking results below).  
Compound Docking in GPR55 Inactive State (R) Model – Docking studies 
identified the putative binding site for ML191 to be the TMH 2-3-5-6-7 region of the 
GPR55 R model. K2.60(80), the only positively charged TMH residue in the putative 
binding site, was used as the primary interaction site for all the ligands docked. Figure 
15A illustrates the final ML191/GPR55 R complex obtained using Induced Fit. The 
ML191 1,3,4-oxadiazo-2-one carbonyl oxygen forms a hydrogen bond with K2.60(80). 
The hydrogen bond (N-O) distance and (N-H—O) and angle are 2.81Å and 154º 
respectively. ML191 forms a number of aromatic stacking interactions. The 
methylphenyl ring next to the cyclopropyl group forms a stack with the EC2 loop residue 
F169 (ring centroid to centroid distance is 5.08Å and the angle between ring planes is 
55º). The pendant phenyl group adjacent to the 1,3,4-oxadiazo-2-one ring stacks with 
F6.55 (246). The ring centroid to centroid distance is 5.41Å and the angle between ring 
planes is 50º. The total pairwise interaction energy for ML191 with GPR55 is -33.16 
kcal/mol. The major interaction energy contributions for this compound are the hydrogen 
bonding interaction with K2.60(80) and Van der Waals interactions with M7.39 (274). 
Aromatic stacking interactions with F169 and Van der Waals interactions with Y3.32 
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(101) also contribute to the interaction energy. The remainder of the aromatic stacking 
interactions identified contribute less to the overall interaction energy. The pendant 
phenyl group prevents a change in the 1 of the toggle switch residue, M3.36 (104) and 
therefore keeps GPR55 in the inactive state.  
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APPENDIX B 
 
SUPPLEMENTAL INFORMATION FOR CHAPTER IV 
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Table S1 
 
ML184/GPR55 R* Complex Interaction Energy 
 
GPR55 B&W Electrostatic (kcal) Vdw (kcal) 
Total Interaction 
Energy (kcal) 
K2.60(80) -8.0 -1.4 -9.4 
Y3.32(101) -3.1 -5.1 -8.2 
F6.55(246) -0.1 -5.0 -5.1 
V6.51(242) -0.1 -4.5 -4.6 
F5.47(190) -0.1 -4.0 -4.0 
M7.39(274) -0.1 -3.7 -3.8 
F3.33(102) -0.1 -3.7 -3.8 
H(170) -2.7 -0.8 -3.5 
F5.39(182) -0.1 -3.1 -3.2 
E5.43(186) -0.4 -1.9 -2.2 
L5.42(185) 0.3 -2.2 -2.0 
M3.36(105) 0.1 -1.9 -1.8 
Y3.37(106) 0.4 -1.4 -1.0 
M(172) 0.2 -1.2 -1.0 
N7.43(278) 0.2 -0.8 -0.6 
L7.35(270) 0.0 -0.6 -0.6 
H1.39(27) 0.0 -0.3 -0.3 
H6.52(243) 0.0 -0.2 -0.2 
P6.50(241) -0.1 -0.2 -0.2 
G5.46(189) 0.1 -0.2 -0.2 
S7.42(277) 0.1 -0.3 -0.2 
M2.61(81) 0.0 -0.2 -0.2 
Q1.35(23) 0.1 -0.3 -0.1 
L2.57(77) 0.0 -0.2 -0.1 
I4.60(156) 0.0 -0.1 -0.1 
Q6.58(249) 0.1 -0.2 -0.1 
L2.53(73) 0.0 -0.1 -0.1 
E3.29(98) 2.2 -0.7 1.5 
 -10.6 -45.3 -55.9 
-55.9 Interaction E (kcal/mol) 
1.91 Ligand Conformational Cost (kcal/mol) 
-54.0 Total Interaction Energy (kcal/mol) 
 
